From improved management of acute pain to prevention of persistent postoperative pain by Tiippana, Elina
University of Helsinki
Department of Anaesthesia and Intensive Care
Helsinki University Central Hospital
Helsinki, Finland
FROM IMPROVED MANAGEMENT OF 
ACUTE PAIN 
TO PREVENTION OF PERSISTENT POSTOPERATIVE 
PAIN
Elina Tiippana
ACADEMIC DISSERTATION
To be presented, with the permission of the Medical Faculty of the University of Helsinki,
for public discussion in the Auditorium of Haartman Institute, Haartmaninkatu 3
on September 13th 2013, at 12 noon
Helsinki 2013
 SUPERVISED BY:
Professor Eija Kalso
University of Helsinki and Department of Anaesthesia and Intensive Care, 
Emergency Care and Pain Medicine, Pain Clinic, Helsinki University Hospital,
Helsinki, Finland
REVIEWED BY:
Docent Mikko Pitkänen
Orton Hospital, Invalid Foundation, University of Helsinki and Department of 
Anaesthesia and Intensive Care, Emergency Care and Pain Medicine, Helsinki 
University Hospital,
Helsinki, Finland
Docent Nora Hagelberg
Turku University Hospital, Department of Anaesthesia and Intensive Care, 
Emergency Care and Pain Medicine, Pain Clinic, 
Turku, Finland
OFFICIAL OPPONENT:
Docent Tuula Manner
Turku University Hospital, Department of Anaesthesia and Intensive Care, 
Emergency Care and Pain Medicine, 
Turku, Finland
ISBN 978-952-10-9045-5 (paperback)
ISBN 978-952-10-9046-2 (PDF)
Helsinki University Print
Helsinki 2013
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ABSTRACT
Background and aims: Treating and preventing acute and persistent postoperative 
pain remains a challenge for health professionals. Patients are discharged to their 
homes far earlier than they previously have been, and pain management protocols 
are needed to accommodate this. After many types of operations, pain may 
persist for months in some patients and it is important to identify those patients 
at risk, treat their pain and to develop methods that decrease the incidence of 
persistent pain. One very painful operation with a high incidence of chronic pain is 
thoracotomy. As invasive pain management is not always possible, adjuvant drugs 
are an important component of multimodal analgesia. The main purpose of this 
study was to investigate the intensity of acute postoperative pain, the incidence of 
chronic pain after surgery, and to explore the possibilities of infl uencing these by 
focusing on thoracotomy and laparoscopic cholecystectomy (LCC) as examples. 
Another objective of this research was to assess the effi cacy of opioid-sparing drugs, 
such as perioperative gabapentinoids, dexamethasone, NSAIDs and paracetamol in 
acute postsurgical pain management. This project also analyzed whether tropisetron 
abolishes the analgesic action of paracetamol.
Material and main methods: Studies I and IV included patients who were 
scheduled for thoracotomy for lung surgery. Study I (n=111) was a prospective, 
clinical follow-up study, and postoperative pain was treated with thoracic epidural 
analgesia (TEA, n=89), intravenous patient-controlled analgesia with oxycodone 
(IV-PCA, n=18) or with intramuscular opioids (n=4), providing all patients with 
regular NSAIDs/paracetamol. The patients’ perioperative data were recorded and 
they were contacted 1 week, 3 months, and 6 months after discharge. Study IV was 
a prospective, randomized and partially double-blind clinical study enrolling 30 
elective study patients (intervention group) and 111 standard care patients (control 
group). The intervention patients were divided into three groups (n=10 each): G1, 
perioperative diclofenac + IV-PCA morphine during pleural drainage + intercostal 
nerve block; G2, perioperative pare-/valdecoxib + IV-PCA morphine + ic-block; and 
G3, paracetamol + patient-controlled epidural analgesia (PCEA) with a background 
infusion of bupivacaine with fentanyl. The perioperative data were extensively 
recorded and the Study IV patients were contacted using the same procedure as in 
Study I. The control patients’ data from the perioperative period were extracted, and 
a prospective follow-up questionnaire was mailed to the patients at six months after 
their surgery, and this procedure was similar to the questionnaire administered to 
the intervention group. Study II was double-blinded and 160 day-case LCC patients 
were randomized to 4 groups (n=40 each). Groups 1 and 3 received pare-/valdecoxib, 
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and Groups 2 and 4 paracetamol perioperatively and also at home for 7 days. In 
addition, Groups 3 and 4 were given dexamethasone intra-operatively. Study III 
was a systematic review with a meta-analysis including 22 randomized, controlled 
trials on the perioperative administration of gabapentin (21) and pregabalin (1) for 
postoperative pain relief. Study V consisted of 2 randomized, double-blind, crossover 
studies with 18 healthy male volunteers in each. The pain stimuli were the cold 
pressor test (CPT), contact heat pain (Study 1) and electrical stimulation (Study 2). 
Tropisetron 5 mg IV or saline were then administered, followed by paracetamol 
2 g IV 30 min later. The individual changes in pain intensity and tolerance were 
recorded and also expressed as a percentage of the individual score at baseline. The 
literature on the interaction of paracetamol with setrons was subsequently reviewed.
Results: Thoracic epidural analgesia was especially effective in alleviating 
movement-related pain after thoracic surgery. One week after discharge, 92-100% 
of the patients needed daily pain medication and 71-77% required weak opioids. In 
Study I (TEA group), the incidence of chronic pain disturbing daily life at 6 months 
was 12%, and in Study IV, these numbers were 3% in the intervention group versus 
24% in the control group (p<0.01). Diclofenac and valdecoxib provided similar 
analgesia and the groups were combined (Study IV). The duration of pain after 
coughing was shorter in the PCEA group than in the NSAID+IV-PCA group, and 
mechanical hyperalgesia was related to more pain when moving. Study II found 
that dexamethasone signifi cantly reduced the need for oxycodone later in the Phase 
2 postanaesthesia care unit (PACU) after LCC. The pain intensity was similar in 
all groups during the fi rst week at home, but more patients in the coxib groups 
needed rescue medication than those in the paracetamol groups. Shoulder pain in 
all groups continued for several days postoperatively. The systematic review (Study 
III) indicated that pain relief was signifi cantly better in the gabapentin groups. The 
consumption of opioids 24 h after a single dose of preoperative gabapentin 300-
1200 mg was reduced by 20-62%, which is comparable to a reduction in morphine 
equivalent doses by 30+4 mg (mean+95% CI). Gabapentin also reduced opioid-
related adverse effects, such as nausea, vomiting and urinary retention (NNTs 25, 
6, and 7, respectively). In Study V, paracetamol 2 g IV did not display a statistically 
signifi cant analgesia on the thermal (Study 1) or electrical pain stimulation tests 
(Study 2). After calculation of the sensory and pain scores, tropisetron seemed to 
amplify the analgesic action of paracetamol.
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ABSTRACT
Conclusions: The extended protocol for pain management in hospital, which 
also covers the sub-acute phase at home, was found to be more important than 
any particular analgesic technique in itself in preventing acute and persistent post-
thoracotomy pain. The value of a strict pain management protocol was also evident 
after LCC in the acute phase. An antiemetic technique + multimodal pain treatment 
with NSAIDs/paracetamol and dexamethasone enabled smooth outpatient LCC. 
The opioid-sparing and pain alleviating role of perioperative gabapentinoids was also 
demonstrated in a systematic review. However, the previously suggested interaction 
in which tropisetron abolished the analgesic action of paracetamol was not supported 
in an experimental volunteer study.
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1. INTRODUCTION
The rapid development of surgery creates new challenges for the management of 
acute postoperative pain. According to the concept of fast-track surgery, patients 
are discharged much earlier than they have been previously and therefore the 
pain management protocols are needed to enable this. An unplanned overnight 
admission rate after a common day-case operation, a laparoscopic cholecystectomy 
(LCC), was 37% in a large Finnish study (1). Successfully conducted ambulatory 
surgery requires multimodal pain treatment, because poorly controlled pain and 
postoperative nausea and vomiting (PONV) are the most common reasons for 
delaying a patient’s discharge home (2). 
After several common operations, acute postoperative pain can be followed by 
persistent pain and for this reason, the ability to screen and treat the patients at 
risk is extremely important. The International Association for the Study of Pain 
(IASP) has defi ned persistent postoperative pain as a pain state that is apparent 
more than two months after surgery and that cannot be explained by other causes, 
such as a recurrence of disease, infl ammation, etc. However, this defi nition is overly 
simplistic, because after undergoing some surgical procedures, an infl ammatory 
response may continue far longer than three months (3). Since chronic pain can 
be severe in four to ten per cent of these patients, this represents a major clinical 
problem that is poorly recognized (4-7). 
One of the most painful operations known is thoracotomy. The incidence of 
chronic post-thoracotomy pain after a year postoperatively is approximately 21-67%, 
and 3-5% of these patients suffer from severe disabling pain (8-14). The gold standard 
in managing post-thoracotomy pain has been thoracic epidural analgesia (TEA). 
However, TEA is an invasive method that can cause serious adverse effects, and 
technical failures are common. After Breivik et al. (15) published “Nordic Guidelines 
for Neuraxial Blocks in Disturbed Haemostasis”, the feasibility of epidural analgesia 
diminished and the necessity increased for alternative methods that are less invasive. 
The safety and effi cacy of pain treatment is increased by using a combination 
of pharmacologically different analgesics. Opioid-sparing drugs are an important 
component of multimodal analgesia, which enables a reduction in opioid 
consumption as well as in the adverse effects that are opioid-induced. For example, 
non-steroidal anti-infl ammatory drugs (NSAIDs), paracetamol, gabapentinoids (16-
21), and glucocorticoids, such as dexamethasone (22-26), are currently considered 
to be an integral part of the postoperative pain management. 
Paracetamol was discovered over a century ago, but its mechanism of action 
remains a mystery. In experimental studies on rats, a specifi c 5-HT3 antagonist, 
intrathecal tropisetron, was reported to have abolished the antinociceptive action of 
14
1. INTRODUCTION
paracetamol (27, 28). Furthermore, in two studies on healthy volunteers, Pickering 
et al. (29, 30) reported the same interaction. This would suggest that paracetamol 
reinforces the descending serotonergic pathways that are involved in the pain 
inhibition in humans. Paracetamol is commonly used for postoperative and cancer-
related pain, concomitantly with the setrons that prevent and manage the nausea and 
vomiting that are induced postoperatively and that follow chemotherapy treatment. 
Therefore, any recommendations regarding the co-administration of these drugs 
need to be based on strong evidence.
The main purpose of the present work was to investigate the intensity of acute 
postoperative pain, incidence of chronic pain after surgery as well as the possibility of 
infl uencing these with extended protocol for pain management, using thoracotomy 
and laparoscopic cholecystectomy as examples. Moreover, an analysis was conducted 
of the relevance of opioid-sparing drugs, such as gabapentinoids, corticosteroids, 
NSAIDs and paracetamol, in the treatment of acute postoperative pain. Additionally, 
one objective of this thesis is to offer some answers to the question of whether 
tropisetron interferes with the analgesic action of paracetamol.   
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2. REVIEW OF THE LITERATURE
2.1. CONSEQUENCES OF ACUTE POSTOPERATIVE PAIN
Even though surgical techniques have been developing continuously, acute 
postoperative pain remains a challenge. Poorly treated pain causes numerous adverse 
effects. For instance, endocrine responses include a burst of catabolic hormones and 
a reduction in anabolic hormones, and metabolic changes (31, Table 1). As a result, 
patients who suffer from acute postsurgical pain are susceptible to hypertension and 
to tachycardia and also have an increased risk of cardiac ischaemia and arrhythmias, 
diminished diuresis, reduced gastrointestinal motility and impaired immune 
function. In addition, due to the pain they are experiencing, patients are unable 
to cough effectively and this might cause pulmonary complications, particularly 
for those patients undergoing thoracic or upper abdominal surgery (32, 33). More 
attention needs to focus on the adequate management of acute postsurgical pain, 
because without it, the patients’ recovery and discharge from hospital may be 
prolonged, and the consequence could be the human suffering.
Table 1. Metabolic and endocrine responses to injury. Adapted from Burton et al. (31).
Endocrine    Catabolic hormones  ACTH, cortisol, ADH, growth hormone,    
    catecholamines, angiotensin II, aldosterone,   
    glucagon, cytokines (interleukins, TNF)
  Anabolic hormones  Insulin, testosterone
 Others    β-endorphins, prolactin
Metabolic  
Carbohydrate Hyperglycaemia, glucose   Glycogenolysis, gluconeogenesis
   intolerance, insulin resistance (cortisol, glucagon, growth hormone,   
     adrenaline, free fatty acids)
      Insulin
Protein Muscle protein catabolism,  Cortisol, adrenaline,    
   acute phase proteins  glucagons, interleukins, TNF
Lipid   Lipolysis and oxidation    Catecholamines, cortisol,
     glucagon, growth hormone
ACTH=adrenocorticotrophic hormone; ADH=antidiuretic hormone; TNF= tumour necrosis factor
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2. REVIEW OF THE LITERATURE
2.2. FROM SINGLE MODE TO MULTIMODAL ANALGESIA IN PRE-
VENTING AND TREATING ACUTE POSTOPERATIVE PAIN
Over 20 years ago, clinicians began to realize the value of the effi cient treatment 
of postoperative pain by reducing the pain-related complications after surgery to 
facilitate earlier mobilization and rehabilitation. Since adequate pain relief cannot 
be achieved by a single agent or method without signifi cant side effects, clinicians 
focused on combinations of analgesic drugs and methods (34). This focus occurred 
because acute postsurgical pain involves multiple mechanisms that ideally require 
a multimodal (“balanced”) analgesia by combining drugs and techniques that act 
at different sites within the central and peripheral nervous systems. These additive 
or synergistic effects improve the analgesia and have opioid-sparing properties that 
decrease the opioid-related adverse effects (35-38). Multimodal analgesia was fi rst 
described by Kehlet and Dahl (39), and this strategy is currently recommended for 
pain relief following both minor and major surgery (Figure 1). 
One cause for the variable success of pharmacologic pain treatment is the 
different genetic disposition of the patients in terms of how much pain they perceive 
after encountering noxious stimuli or how they respond to analgesics. The patient’s 
phenotype is regarded as being a result of the synergistic or antagonistic effects of 
several genetic polymorphisms. These polymorphisms modulate the perception of 
pain. They also alter the pharmacokinetic mechanisms that control the availability 
of active analgesic molecules as well as the pharmacodynamic interactions of 
analgesics with their target receptors. With the complex nature of pain involving 
various mechanisms, a multigenic approach to genetics could be required to 
tailor individualized pain therapy to the patient’s genotype (40). For example, the 
natural variation in the μ-opioid gene OPRM1 may predict increased pain and 
analgesic use following thoracotomy (41), and research suggests that the catechol-
O-methyltransferase gene (COMT) modulates opioid activity and associates with 
postsurgical pain intensity (42). However, many other factors, such as environment 
and the patient’s psychologic vulnerability, expressed as catastrophising and anxiety, 
also affect the patient’s pain experience. Therefore, methods such as patient-
controlled analgesia (PCA) could be useful to enable the patients to modulate their 
own pain treatment, taking account of their individual need for analgesics.
17
2.2.1. OPIOIDS
For the treatment of moderate to severe postoperative pain, opioids are still the 
mainstay of systemic analgesia. Of all opioids, morphine remains the standard 
against which the other opioids are compared. One of its metabolites, morphine-6-
glucuronide (M6G), contributes to analgesia and to adverse effects (43). Another mu-
opioid receptor (OPR) -agonist, oxycodone, is more potent than morphine, which 
could be explained by an active transport system through the blood brain barrier 
(44). In addition, intravenous fentanyl has a fast onset of action and a lack of active 
metabolites, and it is commonly used perioperatively and in the postanaesthesia 
care unit (45). In comparison, the opioids that are not commonly used for acute 
postsurgical pain in Finland are hydromorphone, pethidine and buprenorphine 
(an agonist-antagonist).
Strong opioids may be administrated orally, intravenously, intramuscularly, 
subcutaneously, via neuraxial (epidural or intrathecal), intranasal or peripheral 
routes. Particularly morphine and oxycodone may be administered via intravenous 
patient controlled analgesia (IV-PCA) device (46), which provides better analgesia 
than the conventional parenteral opioid regimens. In a clinical setting, patients 
who were given IM opioid analgesics were more than twice as likely to experience 
moderate to severe pain as those who were given IV-PCA (47). For example, 
Ballantyne et al. (48) reported a non-signifi cant trend towards lower opioid use 
in PCA patients, but studies published since then have reported confl icting results 
Ascending pathway 
Descending pathway 
PAIN  
1 . Transduction 
NSAIDS (COX1/COX2 -inhibitors),   
local anesthetics, opioids 
2. Conduction 
Peripheral nerve block,  
local anaesthetics (Na+- 
channel blockers) 
3. Transmission 
Epidural block, 
opioids, clonidine, 
gabapentinoids, 
COX2- inhibitors 
4. Modulation  
Opioids,  clonidine,  
paracetamol,  COX2- 
inhibitors,  ketamine,  
gabapentinoids  
5. Perception 
Opioids, 
paracetamol, 
ketamine, 
gabapentinoids?
 
 
 Pharmacological intervention along  
pain pathways  
     
                    
DRG 
DRG=dorsal root ganglion; 5HT=serotonin, NA=noradrenaline, 
end.op=endogenous opioids, dopa=dopamine 
5HT 
NA 
end.op 
dopa 
Spinal cord (dorsal horn) 
Figure 1. Multimodal approach to acute pain management. Adapted from Chandrakantan et al. (36).
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(49). In a Cochrane review, IV-PCA led to higher opioid consumption but was 
still safe if background infusion was not used and if the patients were carefully 
observed (50). It is possible that the difference in opioid consumption may not 
refl ect a true difference between the analgesic regimens, but may simply be due to, 
for instance, nurse availability or be a result of the nurse’s assessment of pain and 
need for opioid administration. Pettersson et al. (51) found that pain relief after 
cardiac surgery using IV-PCA was comparable to the nurse-managed IV opioids 
while patients were in an intensive care unit where the nurse: patient ratio was 1:1. 
However, when the patients were transferred to a general ward, signifi cantly better 
analgesia was achieved with PCA.
The neuraxial administration of opioids is based on spinally mediated analgesia 
via the presynaptic and postsynaptic receptors in the substantia gelatinosa in the 
dorsal horn. Neuraxial opioids also potentiate the descending inhibition from the 
μ-opioid receptor activation in the periaqueductal area of the brain (52). When 
intrathecally administered, hydrophilic opioids, such as morphine, have a slower 
onset of action and have longer half-lives in the cerebrospinal fl uid with greater 
spinal cord bioavailability and cephalad migration as compared to the lipophilic 
opioids, such as fentanyl. A meta-analysis (53) reported a greater risk of respiratory 
depression as well as of nausea and vomiting with intrathecal morphine doses of 300 
μg or more compared to lower doses. Furthermore, when epidurally administered, 
hydrophilic morphine has the slowest onset and offset of action and the highest 
bioavailability in the spinal cord (54). However, evidence is confl icting as to whether 
epidural fentanyl acts via spinal absorption rather than via systemic absorption (54, 
55, 56). An infusion of epidural fentanyl appears to produce analgesia by uptake into 
the systemic circulation, whereas a bolus dose of fentanyl acts via a selective spinal 
mechanism (57). The adverse effects caused by systemic opioids may be reduced 
by the epidural administration of opioids, and a signifi cant improvement has been 
demonstrated in postoperative analgesia and a reduction in motor blockade when 
opioids are added to epidural local anaesthetics (58, 59). 
Tramadol is a weak opioid agonist and a serotonin as well as a noradrenaline 
reuptake inhibitor, and it is also effective in the treatment of neuropathic pain. 
As a sole agent, tramadol may not provide adequate pain relief for moderate or 
severe acute postsurgical pain (60). Ten per cent of another weak opioid, codeine, 
is metabolized to morphine. The analgesic action of codeine also depends on 
the patient’s metabolic activity of the CYP2D6 cytochrome P450 isoenzyme. For 
example, poor metabolisers (8-10% of Caucasians) do not benefi t from codeine, and 
ultra-rapid metabolisers (3-5%) generate signifi cantly higher levels of morphine (61). 
Furthermore, codeine is available only in a peroral combination with paracetamol 
or ibuprofen. 
Opioids also have dose-related adverse effects, such as respiratory depression, 
sedation, pruritus, nausea and vomiting, a slowing of the GI function and urinary 
19
retention. For these adverse effects, therefore, opioid-sparing drugs and analgesic 
techniques are recommended (62). The incidence of some common adverse effects 
of opioids is presented in Table 2. After colon surgery, the incidence of postoperative 
ileus varies from 3% to 24%, depending on the amount of opioids administered 
postoperatively (63). However, one drawback is that treatment with opioids may lead 
to both opioid-tolerance (a desensitization of antinociceptive pathways to opioids) 
and paradoxically, to opioid-induced hyperalgesia (OIH), which is a sensitization 
of the pronociceptive pathways, leading to pain hypersensitivity. These phenomena 
can signifi cantly reduce the analgesic effect of opioids. The mechanisms underlying 
the development of tolerance and OIH are thought to include the activation of the 
central glutaminergic system via the NMDA receptor, as well as other transmitter 
and receptor systems (64-66). 
Opioids may also be involved in tumour growth. Recent epidemiologic studies 
indicate a positive association between administering perioperative opioid and 
tumour progression. For example, Lennon et al. (67) demonstrated that the 
overexpression of the opioid receptors in a human non-small cell lung cancer cell 
line increased tumour growth and metastasis, supporting the role of opioid receptor 
activation in tumour progression. Furthermore, breast cancer-specifi c mortality was 
signifi cantly reduced in patients who had a genetic variant in the μ-opioid receptor 
that reduces opioid response (68). Clinical studies on the immunosuppressive effects 
of opioids during surgery are complex because pain itself may suppress immunity 
by producing endogenous opioids. Nonetheless, the use of regional anaesthetics is 
recommended to minimize immunosuppression. Moreover, the possible therapeutic 
role of peripherally restricted μ-opioid antagonists (for example, methylnaltrexone) 
on cancer growth and metastasis also deserve further study (69).
Table 2. Incidence of common adverse eff ects of opioids for postoperative pain. Adapted from 
Dolin & Cashman (62), Hudcova (50) and Barletta (63).
Adverse eff ect IM opioids iv-PCA opioids Epidural opioids
Respiratory depression
(respiratory rate <10 bpm) 1% 1% 1%
Nausea 17% 32% 19%
Vomiting 22% 21% 16%
Pruritus 3% 14% 16%
Excessive sedation* 5% 5% 1%
Urinary retention 15% 13% 29%
IM=intramuscular; bpm=breaths per minute; excessive sedation=”oversedated, deeply asleep/
hard to rouse”, VAS >3/10.
Greater incidence of nausea and pruritus with iv-PCA compared to IM-opioids may be due to 
higher opioid consumption with iv-PCA
(Hudcova 2006).
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2.2.2. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 
Cyclooxygenase (COX) is an enzyme responsible for the formation of important 
biological mediators called prostanoids, including prostaglandins, prostacyclin and 
thromboxane. At present, two COX isoenzymes are known: COX-1 and COX-2 
(Figure 2). Non-selective NSAIDs (for example, diclofenac, ketoprofen, ketorolac, 
ibuprofen, naproxen) and COX-2 selective NSAIDs, which are referred to as “coxibs”, 
such as parecoxib, celecoxib, etoricoxib, all act by inhibiting the prostaglandin 
synthesis in the peripheral tissues, nerves, and in the central nervous system (CNS) 
(70). These are integral components of the multimodal postoperative analgesia 
with an opioid-sparing effect of approximately 40% (71). Perttunen et al. (72) 
demonstrated that after thoracotomy, diclofenac infusion decreases the need for 
an opioid by 75%. However, non-selective NSAIDs have many adverse effects, such 
as irritating the GI tract and impairing platelet aggregation, causing postsurgical 
bleeding. Even though the coxibs are safer in terms of these risks, they have been 
reported to increase the risk of thromboembolic complications after coronary 
artery bypass grafting (CABG) in those patients with atherosclerotic disease (73), 
but not after non-cardiac surgery (74, 75). Mainly due to these cardiovascular risks, 
valdecoxib and rofecoxib were globally withdrawn in 2005. In contrast, valdecoxib 
and its prodrug, parecoxib, produce effective postoperative analgesia and decrease 
opioid requirement by 30-40% (76). Diclofenac and valdecoxib also have been shown 
to cross the blood-brain barrier and they could prevent central sensitization and 
even chronic pain (77-79). However, no fi rm evidence has thus far been reported 
on the overall benefi ts of coxibs over non-selective NSAIDs with postoperative 
analgesia (80). 
Arachidonic acid  
COX-1  COX-2  
Physiologic 
stimulus 
Inflammatory 
stimulus 
Constitutive Inducible 
TXA2     PGI2      PGE2 PGI2                PGE2 
”Housekeeping”                                                             Inflammation  
Gastrointestinal tract           
Kidneys 
Platelet function 
Macrophage differentiation 
inhibition 
undesirable 
inhibition  
desirable 
Cytokines (IL-1, TNF) 
Growth factors 
+  
Glucocorticoids 
Cytokines (IL-4) -  
IL=interleukin; PG=prostaglandin;
TXA=tromboxane; 
TNF=tumor necrosis factor
 
 
Figure 2. The function of COX-1 and COX-2 enzymes. Adapted from Brzozowski T et al, J Physiol Pharmacol 
2005; 56:33-55.
21
2.2.3. PARACETAMOL
2.2.3.1. The mechanism of action of paracetamol
Paracetamol is a weak analgesic because to achieve at least 50% pain relief after 
surgery, the NNT (number-needed-to-treat) for paracetamol 1 g perorally, is 3.6 
(81). According to the meta-analysis by Remy et al. (82), paracetamol combined 
with IV-PCA morphine induced a 20% morphine-sparing effect without reducing the 
adverse effects related to morphine. Paracetamol also crosses the blood-brain barrier 
(83), and its analgesic action may be mediated via the central anti-infl ammatory 
pathways. Moreover, the earlier theory on the inhibition of the cyclo-oxygenase-3 
enzyme (COX-3) has been abandoned (84). Paracetamol may also act in the central 
nervous system as a selective COX-2 inhibitor, where the concentration of tissue 
peroxides is low, contrasting the sites of infl ammation (85, 86). The indirect 
activation of cannabinoid (CB1) receptors also explains part of the analgesic action 
of paracetamol, as well as some of its subjective effects, such as euphoria, relaxation, 
and the feeling of tranquility (87-89). 
2.2.3.2. Possible interaction of paracetamol and 5HT3-antagonists
Pelissier et al. (27) and Alloui et al. (28) have demonstrated in studies using rats 
that intrathecal tropisetron, a specifi c 5HT3-antagonist, completely abolishes the 
antinociceptive action of paracetamol. Because paracetamol does not bind to 5HT 
receptors in vitro, the serotonergic action would be indirect (89). However, other 
5HT3-antagonists (ondansetron, granisetron) administered intrathecally did not 
attenuate the antinociceptive effect of paracetamol, suggesting that the antagonistic 
effect of tropisetron would be mediated through a specifi c receptor that is sensitive to 
tropisetron (89, 90). Recently, these results have been questioned after controversial 
fi ndings have been published concerning the ability of ondansetron to attenuate 
the analgesic action of paracetamol in mice (91, 92).
Two studies on healthy volunteers, conducted by Pickering et al. (29, 30), 
suggested that paracetamol reinforces the descending serotonergic pathways that 
are involved in pain inhibition in humans. Pain was measured by an electrical 
median nerve stimulation (PainMatcher®) (29) and mechanical pain threshold 
before and after a cold pressor test (CPT) (30). The result was that both tropisetron 
and granisetron completely blocked the analgesic action of paracetamol 1g perorally 
due to a pharmacodynamic interaction. Yet clinical studies have questioned these 
preclinical fi ndings. In some studies, the analgesic action of paracetamol was not 
affected by ondansetron after a hysterectomy (93), or by tropisetron after ear 
surgery (94). Furthermore, Bandschapp et al. (95) observed that both paracetamol 
and tropisetron had a weak analgesic effect in the intracutaneous electrical 
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stimulation test when administered alone to healthy volunteers without any effect 
on hyperalgesia or allodynia. However, when simultaneously administered, the 
analgesic action of both drugs disappeared. Thus as the importance of the possible 
interaction of paracetamol and the 5HT3-antagonists cannot be ignored because 
paracetamol is commonly used to manage postoperative and cancer-related pain, 
and as 5HT3-antagonists are simultaneously administered to manage postoperative 
and chemotherapy-induced nausea and vomiting.
2.2.4. EPIDURAL ANALGESIA
In epidural analgesia, opioids and/or local anaesthetics are continuously 
administered into the epidural space via an indwelling catheter. The common 
epidural local anaesthetics, ropivacaine 0,2 % and levobupivacaine 0,125 %, provided 
similar analgesia without a motor block when infused via thoracic epidural catheters 
during lung surgery (96). These concentrations of epidural local anaesthetics were 
equivalent to 0,125 % bupivacaine after hip surgery (97). The total dose of local 
anaesthetics infused was more important than their concentration or volume after 
thoracotomy (98) and lower abdominal surgery (99). 
Of all the types of abdominal and thoracic surgeries, thoracic epidural analgesia 
(TEA) provides better postoperative pain relief than parenteral opioid administration 
– including IV-PCA (49, 100, 101). In comparison to systemic opioid administration, 
TEA resulted in signifi cantly lower pain scores after abdominal aortic surgery in 
comparison with systemic opioid administration, a reduced duration in intubation 
and mechanical ventilation, and lower rates of cardiovascular complications, including 
myocardial infarction, acute respiratory failure, gastrointestinal complications and 
renal insuffi ciency (102). According to Ballantyne et al. (103), due to its superior 
effi cacy especially in relieving dynamic pain, TEA prevents postoperative pulmonary 
morbidity after lung surgery. Furthermore, combining low concentrations of local 
anaesthetics and opioids (for example, lipophilic fentanyl) has been shown to provide 
superior pain relief when compared to either of the drugs alone (68, 69, 104). 
TEA is, however, an invasive method that cannot be used in every patient due to 
the increasing use of long-acting anti-thrombotic prophylaxis. In a Finnish study all 
claims attributed to central neuraxial blocks and handled by the Patient Insurance 
Centre (PIC) during 2000-2009 were analyzed. Fatalities during perioperative 
epidural pain management occurred in 1:62 000 due to errors in medication, 
unintended total spinal anaesthesia, infection or consequences of nerve damage, 
and the incidence of epidural haematoma was 1:26 400 (105). Much higher incidence 
of epidural haematomas (1:10 300) was found in Sweden during 1990-1999, and 
the risk was up to 1:3 600 in elderly females undergoing knee arthroplasty (106). 
In United States the incidence was  1:4 330 – 1:22 189 (107). Due to these serious 
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risks, the Acute Pain Service (APS; see chapter 2.4.) has a crucial role in observing 
the patients treated with invasive analgesic techniques, such as epidural analgesia 
and IV-PCA opioids (108-110). 
2.2.5. ADJUVANT DRUGS
Adjuvant analgesics are medications that are not primarily designed to control 
pain, but can be used for this purpose. Examples of these drugs are gabapentinoids, 
glucocorticoids and NMDA-receptor antagonists.
2.2.5.1. Gabapentinoids
Gabapentin is an antiepileptic drug that has been extensively used to treat 
diabetic polyneuropathy, postherpetic neuralgia, and neuropathic pain in general. 
The mechanism of action of gabapentin and its successor, pregabalin, has been 
investigated for chronic pain. This mechanism is mediated by selectively binding 
to the α2δ subunits of the presynaptic voltage-gated calcium channels, which are 
upregulated in the dorsal ganglia and in the spinal cord after surgical trauma 
(Figure 3). Gabapentinoids may produce antinociception by inhibiting calcium 
infl ux via these channels, and subsequently by inhibiting the release of excitatory 
neurotransmitters from the primary afferent nerve fi bers in the pain pathway. The 
α2δ subunit is also a receptor for the proteins that promote synapse formation, called 
thrombospondins. The disruption of this synaptogenesis in central nervous system 
by the gabapentinoids may contribute to their analgesic effects. Gabapentinoids 
also inhibit glutamate release, decrease the activity of NMDA-receptors, inhibit 
voltage-gated sodium channels, and enhance the action of voltage-gated potassium 
channels. Additionally, the amplitude of a tonic inhibitory GABAergic conductance 
may be increased by the prolonged use of gabapentinoids. While both drugs lack 
hepatic metabolism and have known pharmacodynamic interactions, pregabalin 
has a more favourable pharmacokinetic profi le than gabapentin (16-21). 
In central sensitization, the excitability of neurons within the central nervous 
system is increased so that normal inputs begin to produce abnormal responses, 
which may occur in association with surgery that causes severe acute pain. 
Gabapentinoids have antiallodynic and antihyperalgesic properties that reduce the 
hyperexcitability as well as the central sensitization of the dorsal horn neurons. 
Gabapentinoids may also reduce opioid tolerance, and they have anxiolytic effects 
(111, 112). 
Gabapentinoids have been widely tested in experimental pain models. Whereas 
the subjective pain ratings were unaffected by gabapentin in the heat pain and 
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the pinprick skin stimulation tests, the studies conducted on functional magnetic 
resonance imaging (fMRI) detected activation in the bilateral insula. However, 
the cold pressor test (CPT) was insensitive to gabapentin. Gabapentin has also 
displayed some analgesic effect against hyperalgesia and allodynia after cutaneous 
capsaicin stimulation, and the modulation of the cerebral response could be clearer 
for neuropathic pain than for acute pain. In addition, the relation between the dose 
and effect of gabapentin has been reported to be nonlinear (113). The allodynia 
and hyperalgesia that arose from continuous electrical stimulation were reduced 
after multiple doses of pregabalin, whereas temporal summation has not been 
determined to be attenuated. In other words, the results from experimental tests 
with gabapentinoids have been somewhat confl icting (113, 114).
In recent years, gabapentinoids have been introduced as adjuvants into the 
multimodal management of acute postoperative pain. A single preoperative dose 
of gabapentin has been suggested to reduce pain intensity, opioid consumption and 
opioid-related adverse effects for the fi rst 24 h (115-120), but a low dose of gabapentin 
(250 mg) for the treatment of established postoperative pain was determined to 
be of limited clinical value (121). An optimal dose of pre-emptive gabapentin was 
then evaluated for administration before back surgery, and a large single dose of 22 
mg/kg was found to be needed for analgesic effi cacy (122). However, the focus of 
research has recently shifted to the perioperative use of pregabalin, which has been 
shown to produce a dose-related reduction in postoperative opioid consumption 
(123-125). Whereas the administration of 225-300 mg/day of pregabalin during 
a short perioperative period provided additional analgesia, it also created some 
adverse effects, such as dizziness and visual disturbances (123). In a Cochrane review, 
Moore et al. (126) detected no clear evidence of the benefi cial effects of pregabalin 
in acute postsurgical pain, and the effi cacy of pregabalin in acute postoperative pain 
was suggested to be somewhat dependent on the type of the surgery (127, 128). 
Ca++ 
Ca++ 
GBP/PGB 
GBP=gabapentin; PGB=pregabalin
Modifi ed from: Khosravani H & Zamponi 
GW. Physiol Rev 2006; 86:941-66.
Figure 3. The binding site of gabapentinoids. 
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2.2.5.2. Glucocorticoids
A popular subject of research concerning the prevention of postoperative nausea 
and vomiting, and to a lesser extent, postoperative analgesia, has been systemic 
glucocorticoids. A safe and effective method that has been proven to reduce the pain 
from orthopaedic and breast surgery (129, 130) is methylprednisolone IV. One strong 
anti-infl ammatory glucocorticoid with antinociceptive effects is dexamethasone. The 
effect of this glucocorticoid is to inhibit glial activation, sympathetic sprouting, the 
production of prostaglandins, bradykinin, leukotriens, TNF-α and other mediators 
of infl ammatory hyperalgesia and central sensitization, including the systemic acute-
phase response and the C-reactive protein (CRP) levels (22-26). Glucocorticoids 
also inhibit the synthesis of COX-2 in both the peripheral tissues and the central 
nervous system (131). The systemic analgesic effect of glucocorticoids has also been 
demonstrated after dental, anorectal and lumbar disc surgery, tonsillectomy and 
LCC, and they may reduce postoperative fatigue and PONV (132-136). Doses as 
high as methylprednisolone 30 mg/kg and dexamethasone 40-80 mg IV have been 
proven to be safe (134, 135, 137). The advantages of the preoperative administration 
of an intermediate dose of dexamethasone (0.1-0.2 mg/kg IV) is that it reduces 
postoperative pain and opioid consumption after various surgical procedures 
without any major adverse effects, apart from minor hyperglycemia at 24 h (138, 
139).
The activation of the metabolic response to surgery occurs immediately after the 
incision. The onset of the biologic action of glucocorticoids takes one to two hours 
by changing the protein-synthesis by gene transcription. Thus, the optimal timing 
of dexamethasone would be one to two hours prior to surgery (140). However, 
glucocorticoids may also have rapid non-genomic effects by acting on the membrane 
receptors and could also therefore be useful also after surgery (141). 
2.2.5.3. NMDA-receptor antagonists
Ketamine is an inexpensive drug that acts as a non-competitive antagonist of the 
NMDA-receptor in sub-anaesthetic doses, although it also binds to many other 
sites in the peripheral and central nervous system. At these doses, ketamine serves 
as an agent that is antihyperalgesic and antiallodynic by inhibiting the TNF-α and 
IL-6 gene expressions that result in subsequent anti-proinfl ammatory effects (142). 
Consequently, ketamine may be used as an adjuvant in the treatment of pain that is 
associated with central sensitization such as in severe acute pain, neuropathic pain 
and opioid-resistant pain (143). Bell et al. (144) reported that low-dose ketamine 
(up to 30 mg/24h) is effective in reducing morphine requirements in the fi rst 24 
hours after surgery, and ketamine also reduces PONV without having clinically 
relevant adverse effects of its own. Additionally, a 0.5 mg/kg IV bolus + 0.25 mg/
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kg/h (4 μg/kg/min) infusion during general anaesthesia has been shown to provide 
long-term analgesia up to 6 months (145). Recently, in treating acute pain after 
thoracotomy, ketamine has also been shown to be a benefi cial part of multimodal 
analgesia (146-150), but negative results have also been published (151).  
It is important to note that the available literature on dextromethorphan for the 
treatment of postoperative pain is heterogenous. Controlled trials demonstrate that 
dextromethorphan does not reduce postoperative pain to a clinically signifi cant 
extent, even though the time to the fi rst analgesic request may be prolonged 
and a decrease in opioid consumption was also observed in the majority of the 
studies where the drug was administered parenterally (152). Hence, the role of 
dextromethorphan in postoperative pain management is still unclear.
2.3. PROCEDURE-SPECIFIC APPROACHES TO POSTOPERATIVE 
PAIN MANAGEMENT
The different types of surgical procedures (for example, orthopaedic, abdominal, 
thoracic and laparoscopic) each entail unique characteristics of postoperative 
pain and adverse clinical consequences, such as immobilization, ileus, urinary 
retention and the impairment of pulmonary function. As a consequence, analgesic 
techniques need to be targeted specifi cally for the procedure. For example, after 
major abdominal and thoracic surgery, continuous epidural analgesia is benefi cial 
in reducing dynamic pain and ileus. Nonetheless, epidural analgesia is an invasive 
method with potential risks and it is not appropriate, for example, for day surgery, 
for some procedures with lower abdominal incisions and for laparoscopies. 
Peripheral nerve blocks and local infi ltration analgesia (LIA) are increasingly used 
after orthopaedic surgery instead of epidural analgesia. In addition, analgesic drugs 
may have different side-effect profi les of analgesic drugs that depend on the type 
of surgery, such as conventional non-specifi c NSAIDs (not the coxibs) that create 
a risk of bleeding after tonsillectomy, hip and knee prosthesis operations, as well 
as after plastic and intracranial surgery (35). 
2.3.1. THORACOTOMY
A perfect example of a major multifactorial postoperative pain is the acute pain 
that occurs after thoracic surgery. Acute post-thoracotomy pain is a combination of 
nociceptive, visceral and neuropathic pain that is evoked by breathing and coughing. 
The origin of the pain is due to incisional pain, the stretching of thorax, a resection 
or fracture of ribs, a dislocation of costovertebral joints, an injury to the intercostal 
nerves, the shoulder pain from a stretching position, and the visceral pain from the 
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irritation of the pleura by thick chest drains (153, Figure 4). If poorly treated, the 
risk of pulmonary complications and chronic pain increases (10, 103). 
Compared to the IV opioids, thoracic epidural analgesia (TEA) provides superior 
analgesia compared to IV-PCA opioids, especially for dynamic pain (154-159). 
Enabling patients to cough properly, TEA is reported to prevent postoperative 
pulmonary morbidity after lung surgery (103, 160-163). In addition, the short-
term quality of life postoperatively may be better with TEA than IV-PCA opioids 
due to better mobility, less sedation, improved compliance with physiotherapy, and 
more effective analgesia (164). 
TEA is an invasive method that can cause serious adverse effects. Technical 
failures are also common (156, 165), and epidural haematomas, abscesses and other 
neurological complications have to be taken into account (see Epidural analgesia 
2.2.4.). Hence, alternative analgesic methods to TEA are still needed in preventing 
acute and persistent post-thoracotomy pain.  
An alternative to TEA is the paravertebral nerve block (PVB) with a bolus of a local 
anaesthetic preoperatively or at the end of surgery, which is followed by a continuous 
infusion via a catheter. Recent data confi rms that PVB is comparable to TEA in 
controlling acute pain after thoracotomy, and that PVB has less haemodynamic 
adverse effects and a lower risk for neurological sequelae (166-168). In a situation 
Figure 4. Origin of post-thoracotomy pain.
Photo by Dr Eija Nilsson
28
2. REVIEW OF THE LITERATURE
where neither TEA nor PVB is possible, it is recommended to use intercostal nerve 
blocks with local anaesthetics or to use IV-PCA with strong opioids. Furthermore, an 
integral part of a multimodal analgesic regimen in managing acute post-thoracotomy 
pain, if not contraindicated, is non-selective NSAIDs/ coxibs or paracetamol, which 
are enhanced later with weak opioids when the pain intensity has decreased to less 
than moderate (169).
2.3.2. LAPAROSCOPIC CHOLECYSTECTOMY
A good example of day surgery that involves moderate pain intensity (visual analogue 
scale, VAS 4-6/10) and sources of pain that are multifactorial is laparoscopic 
cholecystectomy (LCC). The somatic pain component is superfi cial incisional pain, 
and the visceral component is deep intra-abdominal pain caused by intraperitoneally 
insuffl ated carbon dioxide (CO
2
) and bile spillage, causing chemical peritonitis. In 
addition, shoulder pain is referred visceral pain caused by CO
2 
entrapped between 
the liver and the right hemidiaphragm, leading to irritation and stretching of the 
peritoneum. Also use of diathermy in the liver bed produces a systemic infl ammatory 
response and hyperalgesic pain (170). The most common reasons for delaying a 
patient’s discharge home are poorly controlled pain and PONV (2). Therefore, it is 
important to fi nd a multimodal pain treatment, and a suitable PONV-preventing 
anaesthetic technique with infusions of propofol and remifentanil is also needed to 
hasten both the emergence from anaesthesia and postoperative recovery (2, 171). 
2.4. ACUTE PAIN SERVICE
The use of invasive pain management techniques, such as epidural and IV-PCA, 
require close observation of the patients in the surgical ward. In a recent RCT, 
Lee et al. (109) compared an APS led by an anaesthesiologist to conventional pain 
treatment after major surgery. They demonstrated that the proportion of patients 
with highly effective pain management was higher in the APS group than in the 
control group, but with extra costs. However, a nurse-based model would further 
reduce costs, still maintaining the safety of pain management.  APS has also a 
crucial role in recognizing those patients who are at risk of severe acute and chronic 
postoperative pain, and their educational programmes support nurses and doctors 
involved in pain management after surgery. Therefore, this kind of organization 
for the management of postoperative pain is strongly recommended worldwide 
(108, 110).
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2.5. CHRONIC PAIN AFTER SURGERY
2.5.1. MECHANISMS AND PREDICTIVE FACTORS FOR CHRONIC POSTSURGICAL 
PAIN
Many common operations involve acute postoperative pain that is sometimes 
followed by persistent pain. These operations are, for example, breast and thoracic 
surgery, groin hernia repair, leg amputation, and coronary artery bypass surgery 
(Table 3). Acute pain may also become persistent through some pathophysiological 
processes after tissue or nerve injury occurs. An example of these injuries is the 
infl ammation that can occur at the site of tissue damage with a barrage of afferent 
nociceptor activity that produces changes in the peripheral nerves, the spinal cord, 
the higher central pathways (central sensitization) and in the sympathetic nervous 
system (172-174). The mechanical hypersensitivity in the uninjured tissue area that 
surrounds the wound (secondary hyperalgesia) indicates central sensitization after 
surgery, and the extent of this correlates with the risk for chronic postsurgical pain, 
and this has been shown to occur after major abdominal surgery (175). Moreover, 
after limb amputation, the reorganization or remapping of the somatosensory cortex 
and of the other cortical structures may contribute to the development of phantom 
limb pain (176). 
A number of risk factors for the development of chronic postsurgery pain have 
been identifi ed. The following factors may be associated with an increased likelihood 
of persistent pain after surgery: severity of preoperative pain, nerve injury during 
and after the operation, persistent infl ammatory process, genetic susceptibility, 
severity of early postoperative pain and psychosocial factors (4, 5, 174, 177-181, 
Table 4). In addition, a patient’s immune response may also be involved in the 
transition of acute postsurgical pain to chronic pain. This has been demonstrated 
with patients after lateral thoracotomy when chronic postsurgical pain was decreased 
in lung transplanted patients who were treated with immunosuppressive therapy in 
comparison to patients who were operated on lung cancer (182). Another relevant 
factor may be the descending pathways of pain control, as patients with ineffi cient 
diffuse noxious inhibitory control (DNIC) – also referred to as “conditioned 
pain modulation (CPM)” - might have an increased risk of developing acute and 
chronic postsurgical pain (183, 184). It is important to notice that the intensity of 
acute postoperative pain correlates with the risk of persistent pain after surgery. 
Consequently, aggressive early therapy for acute pain could be a mainstay to prevent 
acute pain from converting into a chronic state. However, the transition from acute 
pain to chronic postsurgical pain is a dynamic process that evolves over time. As 
a consequence, assessing outcomes at a single follow-up after surgery does not 
provide information on whether the factors involved in the transition to chronic 
pain differ from those involved in the maintenance of already established chronic 
pain disability (180). 
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Table 3.  Incidence of chronic pain after surgery (3-12 months postoperatively). 
Adapted from Kehlet et al. (4), Macrae (5) and Lavand’homme (7).
Type of operation Incidence of chronic pain     Estimated incidence of chronic   
   (%)              severe (disabling) pain (NRS>5/10) (%)
Limb amputation  30–85   5–10
Thoracotomy 5-65              10
Mastectomy  11-57              5-10
Major abdominal
surgery   7-14              n.a.
Craniotomy  7-29              n.a.
Knee arthroplasty 13               n.a.
Hip arthroplasty 12               n.a.
Cesarean section 4-10               4
Inguinal hernia 5-63               2-4
Coronary bypass 30-50               5-10
Cholecystectomy 3-50               n.a.
Vasectomy  0-37               n.a.
Dental surgery 5-13               n.a.
NRS=numeric rating scale (0-10). n.a.=not available. All numbers are based on both retrospective 
and prospective studies.
Table 4.  Risk factors for chronic postsurgical pain. 
Adapted from Kehlet et al. (4), Macrae (5) and Andersen & Kehlet (179). 
Preoperative factors                      Preoperative pain, moderate to severe, lasting more than  
                                              1 month in the surgical area
        Preoperative chronic pain in other locations  
   
                                                         Repeat surgery (e.g. cancer recurrence)
                                                    Psychologic vulnerability (e.g. catastrophising, anxiety)
                                                        Female gender
    
        Obesity (risk to nerve damage during surgery)
                                                      Younger age (adults)
                                                       Workers’ compensation
                                                    Genetic predisposition
      Ineffi  cient DNIC, diff use noxious inhibitory control   
    (=CPM, conditioned pain modulation)
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Intraoperative factors            Surgical approach with risk of nerve damage
         
    Tissue ischaemia
         
    Proinfl ammatory state
Postoperative factors              Acute pain (moderate to severe), hyperalgesia
     
         Radiation therapy to the surgical area
                   
                                                        Neurotoxic chemotherapy
         Sensory disturbances after surgery
          Surgical complications (infection, seroma, hematoma)
        
           Repeat surgery
      
         Psychological vulnerability, anxiety    
 
        
2.5.2. CHRONIC POST-THORACOTOMY PAIN
The International Association for the Study of Pain (IASP) defi nes post-thoracotomy 
pain syndrome (PTPS) or chronic post-thoracotomy pain as, “pain that recurs or 
persists along thoracotomy incision at least two months following the surgical 
procedure”. Generally, this entails a burning and stabbing pain with dysaesthesia and 
displays many features of neuropathic pain in nearly half of the patients experiencing 
pain (10, 185). The risk of PTPS may be predicted by preoperative pain, female 
gender, younger age, psychological factors, severe acute postoperative pain, high 
consumption of analgesics during the fi rst postoperative week, and the type of 
surgery and complications (11, 12, 186-188). Even muscle-sparing incisions seem 
to have no advantage over posterolateral incisions (189). However, intraoperative 
intercostal nerve damage during thoracotomy is not necessarily associated with PTPS 
(190, 191). Chronic post-thoracotomy pain was commonly diagnosed by surgeons 
during the Second World War in those soldiers who had undergone a thoracotomy 
for chest trauma; this was called “chronic intercostal pain”. Unfortunately, very little 
has changed since then in terms of the numbers of patients with PTPS. 
During the past decade, due to it being a minimally invasive procedure, video-
assisted thoracic surgery (VATS) has partially replaced open thoracotomy for lung 
surgery. This is because rib retractors are not needed in the thoracoscopic approach 
and the integrity of the chest cage is preserved with less trauma to the patient’s 
intercostal nerves and ribs. Therefore, the acute pain that occurs after VATS is 
considerably milder than after a thoracotomy (192, 193). However, VATS also carries 
a risk of nerve damage and a development of persistent pain in 5-47% of the patients, 
yet less risk is involved than after open surgery (188, 194, 195).
Some evidence suggests that TEA could prevent central sensitization and long-
term post-thoracotomy pain (155, 186), but this evidence is still controversial. 
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2. REVIEW OF THE LITERATURE
For example, the “pre-emptive analgesia” attempts to reduce post-injury pain 
hypersensitivity by starting the treatment before the surgical procedure rather than 
afterwards. However, this concept is controversial, and it would be more relevant to 
talk in terms of “preventive analgesia” so that the persistence of the analgesic effect 
after the treatment has ceased. Preventive analgesia is based on the assumption 
that the only way to prevent central sensitization is to completely block any pain 
and afferent signals. This includes a complete humoral blockade of the circulating 
pro-infl ammatory cytokines from the surgical wound, and this occurs from the 
time of the incision until the wound heals (174). Sentürk et al. (196) demonstrated 
that initiating epidural analgesia prior to a thoracotomy incision and continuing 
postoperatively results in signifi cantly less pain in the acute phase and six months 
later compared to IV-PCA opioids or TEA initiated after surgery. In a meta-analysis, 
Bong et al. (197) found that pre-emptive TEA appeared to reduce the severity of 
acute pain without any effect on the incidence of persistent pain. 
The role of opioid-induced hyperalgesia induced by high-dose remifentanil 
cannot be ignored. High-dose remifentanil without epidural analgesia during 
surgery was associated with a large allodynic area around the thoracotomy wound 
and a higher incidence of chronic pain, compared with perioperative low-dose 
remifentanil and TEA (198). Overall, it seems that thoracic epidural anaesthesia 
may be effective in reducing the post-thoracotomy pain syndrome; however, the 
timing of the initiation of the TEA may not be signifi cant (14). 
Some evidence suggests that PVB may decrease the incidence of chronic pain 
after breast surgery which resembles PTPS due to the predominance of neuropathic 
features (199, 200). However, the role of paravertebral blocks in preventing PTPS 
has not been investigated. 
Low-dose ketamine appears to be useful in decreasing acute post-thoracotomy 
pain as part of multimodal analgesia (see Chapter 2.2.5.3.). Unfortunately, there 
is no evidence of a more sustained benefi t in preventing PTPS (201, 202). Senard 
et al. (203) published promising results on the fi rst randomized controlled trial 
(RCT) involving COX-2 inhibitors (celecoxib) with TEA for acute post-thoracotomy 
pain. Nevertheless, there is no literature on the effect of selective or non-selective 
NSAIDs on PTPS. Whereas epidural clonidine, even as a sole agent, has decreased 
acute post-thoracotomy pain (204), no evidence has been found on its long-term 
effects. Gabapentinoids as antihyperalgesic drugs would be an attractive choice for 
the management of acute and prevention of chronic post-thoracotomy pain. The 
results are, however, controversial in acute pain (205, 206), and there is currently 
no literature on the use of gabapentinoids to prevent PTPS.
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3. AIMS OF THE STUDY
The main purpose of the present work was to investigate the intensity of acute 
postoperative pain and incidence of chronic pain after surgery. In addition, an 
analysis will be presented of the possibilities for improving postoperative pain 
management with multimodal analgesia and in preventing persistent pain after 
surgery.  
The specifi c aims were:
1.  To survey the incidence of persistent post-thoracotomy pain (Studies I and 
IV).
2.  To investigate whether the controlled pain management protocol extended 
also to the sub-acute postoperative phase would result in less acute and 
persistent post-thoracotomy pain in comparison to standard “as usual” pain 
management (Study IV).
3.  To evaluate if IV-PCA morphine combined with NSAIDs (non-selective versus 
COX-2 selective), and thoracic epidural analgesia are safe and effective after 
thoracotomy (Study IV). 
4.  To assess the effi cacy of paracetamol or pare/valdecoxib with or without 
dexamethasone following day-case laparoscopic cholecystectomy (Study II). 
5.  To assess the quality of pain relief after thoracic surgery and laparoscopic 
cholecystectomy at home during the fi rst week after a patient is discharged 
(Studies I, II, IV)  
6.  To evaluate RCTs that examine the analgesic effi cacy, adverse effects, and the 
clinical value of gabapentinoids in postoperative pain (Study III, a systematic 
review).
7.  To test whether tropisetron, a 5HT3-antagonist, affects the analgesic effect 
of paracetamol in three different models of acute pain in healthy volunteers 
(Study V).
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4. MATERIAL AND METHODS
Clinical studies I and IV included a total of 252 thoracotomy patients, and in study 
II 160 day-case LCC patients were involved. Study III was a systematic review about 
perioperative gabapentinoids, and Study V was an experimental volunteer study to 
fi nd out the interaction between paracetamol and tropisetron.
4.1. MATERIAL
4.1.1. PATIENTS (STUDIES I, II AND IV)
Studies I and IV included patients who were scheduled to undergo a thoracotomy 
for lung surgery, and these were performed at the Department of Thoracic Surgery 
in Meilahti Hospital, which is a part of the Helsinki University Central Hospital. 
The consecutive patients in Study I were enrolled between April 1999 and August 
2000, and 111 patients in total were analyzed. Both elective and emergency patients 
were included. Study IV examined two different groups of thoracotomy patients: 
an intervention group (n=30) and a control group (n=111). The exclusion criteria 
in the intervention group were contraindications to any of the study drugs or an 
epidural catheter, signifi cant liver, renal or cardiac disease, peptic ulcer, regular 
use of analgesics, re-thoracotomy, and the patient’s inability to understand the 
use of PCA/patient controlled epidural analgesia (PCEA; 207). The patients were 
recruited between April 2004 and September 2008. The control group consisted 
of patients who were treated according to the current standard of care at the clinic.
Study II included 160 patients of the ASA physical status I-II who were scheduled 
for elective ambulatory laparoscopic cholecystectomy (LCC) between the years 2003 
and 2006 at the the Day Surgery Unit of Maria Hospital, which is part of the 
Helsinki University Central Hospital. Other inclusion criteria of the patients were 
their age, that they are between 18 to 60 years and have a body mass index (BMI) 
between 17 and 31. The exclusion criteria included having an allergy to NSAIDs 
or sulphonamides, bronchial asthma, liver or renal disease, peptic ulcer, bleeding 
disorders and regularly using analgesics. One patient was excluded from the analyses 
owing to a reoperation due to bleeding.
4.1.2. STUDIES III AND V
Study III was a systematic review that evaluated 22 RCTs (a total of 1 909 
patients) examining the analgesic effi cacy, adverse effects, and the clinical value 
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of gabapentinoids (gabapentin and pregabalin) in postoperative pain. This review 
covered the literature from 1966 to September 2006. Study V consisted to 2 different 
studies (Study 1 and Study 2), that included 18 healthy male volunteers. Out of the 
18 volunteers who participated in Study 1, 12 also participated in the second study. 
In Study 1/V, the mean age was 23 (SD 3) and the mean BMI was 23 (SD 3), and 
in Study 2, the mean age was 24 (SD 3) and the mean BMI was 24 (SD 3). The 
exclusion criteria included a contraindication to either of the study drugs, smoking 
more than nine cigarettes per day, excessive consumption of tea or coffee (more 
than four cups per day) or taking any medications during the two weeks preceding 
the study. The fi rst study was conducted in July 2009 and the second study was 
conducted in October 2010.
4.2. ETHICAL ISSUES
Studies I, II, IV and V were approved by the Institutional Ethics Committee and 
Studies II, IV and V by the National Agency of Medicine (NAM). A written informed 
consent was obtained from all the patients and volunteers.
4.3. STUDY DESIGNS, PROTOCOLS AND INTERVENTIONS
4.3.1. STUDIES I, II AND IV
Study I is a prospective clinical follow-up study that enrolls all the consecutive 
patients (n=111) who underwent a thoracotomy between 1999 and 2000. This 
study was not randomized nor controlled, because the anaesthesiologist in charge 
selected the method of pain treatment. Thoracic epidural analgesia (TEA) was 
considered to be the standard treatment (n=89; for characteristics of TEA, see Study 
I/Table 2), and the alternatives were IV-PCA with oxycodone and an intrathoracic 
intercostal block with bupivacaine at the end of the surgery (n=18). Four patients 
had conventional pain treatment with intramuscular oxycodone. All patients were 
also administered oral NSAIDs or paracetamol regularly from POD 1, in addition to 
a weak opioid (tramadol or paracetamol with codeine) that was administered after 
discontinuing the TEA or IV-PCA. The patients were prescribed regular ibuprofen 
or paracetamol and tramadol for home and were given instructions on how to take 
the analgesics. The patients were also encouraged to phone the APS nurse when 
needed. All patients were interviewed on the phone using a structured questionnaire 
a week after their discharge, the interview was repeated three and six months after 
the thoracotomy through a mailed questionnaire (Appendix 1).
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4. MATERIAL AND METHODS
Study II is a prospective, randomized, double-blind clinical study that enrolled 
160 elective, ambulatory LCC patients. All patients were given glycopyrrolate and 
tropisetron followed by a general anaesthesia that was induced by fentanyl, propofol 
and rocuronium. The anaesthesia was maintained with infusions of propofol and 
remifentanil, maintaining the bispectral index (BIS) at 40-50. Warm CO
2
 insuffl ation 
was used and intra-abdominal pressure was maintained under 12 mmHg. At the 
end of the surgery, the incisions were infi ltrated with levobupivacaine.
The patients were randomly divided into four study groups. The patients in Group 
1 (n=40) were administered doses of 40 mg of parecoxib 40 mg IV intra-operatively 
followed by an oral dose of 40 mg x1 of valdecoxib for seven days, started in Phase 
2 PACU. The patients in Group 2 (n=40) were given 1g of paracetamol IV, and the 
fi rst dose was administered at the same time as for Group 1. An oral dose of 1g of 
paracetamol was continued four times per day for seven days. Patients in Group 
3 (n=40) were administered parecoxib and valdecoxib similarly to those in Group 
1, and were administered 10 mg of dexamethasone IV which was administered 
intraoperatively. Patients in Group 4 (n=40) were given paracetamol similarly to 
those in Group 2 and 10 mg of dexamethasone IV. The staff nurse who administered 
the study drugs was not otherwise involved in the study. The rescue medications 
in Phase 1 PACU were 0.05 mg/kg of oxycodone IV when the pain measured on a 
visual analogue scale (VAS) was >3, and 0.01 mg/kg of droperidol IV for PONV. 
During Phase 2 PACU, the patients were given 0.15 mg/kg of oxycodone orally when 
needed. The patients were supplied with the study drugs for 7 postoperative days and 
were instructed to take 40 mg of valdecoxib every morning or 1g of paracetamol 4 
times per day as long as needed. All patients were interviewed by phone on the fi rst 
postoperative morning, and they also fi lled in a structured questionnaire for seven 
postoperative days (Appendix 2). This follow-up part of the study was not blinded. 
Study IV included a prospective, randomized and partially double-blind clinical 
study consisting of 30 elective study patients (intervention group), and another 
non-randomized group of 111 control patients (control group) who underwent 
a thoracotomy for lung surgery between 2004 and 2008. The patients in the 
intervention group were randomly divided into three groups: 1) diclofenac + IV-
PCA (n=10), 2) parecoxib/ valdecoxib + IV-PCA (n=10), and 3) PCEA (n=10). All 
patients were premedicated with temazepam. The patients in Groups 1 and 2 received 
oral doses of 75 mg of diclofenac or 40 mg of valdecoxib, respectively. At wound 
closure, a 44-hour IV-infusion began of 150 mg/24h of diclofenac (Group 1) or 80 
mg/24h of parecoxib (Group 2), and an intercostal nerve block with bupivacaine 
was performed. Patients were given an IV-PCA with morphine boluses 2-3 mg and 
a lock-out time of 5 to15 minutes in the PACU. From the second postoperative 
morning onwards, the patients in Group 1 were given oral diclofenac 75 mg x2, and 
the patients in Group 2 valdecoxib 40 mg x2 until discharge. The IV-PCA morphine 
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was discontinued after the removal of the pleural drains, and oral oxycodone was 
provided when needed. The patients in Group 3 received epidural catheters in the 
evening before their surgery. At that time, the catheters were also tested. The PCEA 
patients were administered IV 1g of paracetamol and an epidural loading dose of 
1 ml/10 kg of bupivacaine 1.5 mg/ml with 6 μg/ml of fentanyl at the induction 
of anaesthesia. A continuous infusion began at 1 ml/10 kg/h with an option to 
take incremental doses of 3 ml with a 8-15 min lock-out time. The PCEA patients 
received IV 1g of paracetamol 4 x for the fi rst 24 hours and 1 g x3 orally thereafter. 
PCEA was discontinued and paracetamol was replaced with ibuprofen and oral 
oxycodone after removal of the pleural drains, which is similarly to Groups 1 and 2. 
All patients were prescribed ibuprofen or paracetamol and tramadol for home after 
their discharge from hospital, and they were encouraged to contact the research 
nurse or the researchers when needed, which was the same procedure as in Study I. 
The extended controlled pain management protocol consisted of observation by APS 
seven days a week and prescription of weak opioids for home in addition to NSAIDs 
/paracetamol. Furthermore, the patients were carefully instructed how to use the 
analgesics at home, and they were contacted by phone one week after discharge, with 
a possibility to give further information and prescribe more analgesics if needed. 
The schedule of Study IV is shown in Figure 5.  
The standardized anaesthesia consisted of an induction with glycopyrrolate, 
fentanyl, propofol and rocuronium, and maintained with sevofl urane in a mixture 
of oxygen and air. The depth of anaesthesia was monitored with the BIS. The 
thoracotomy was anterolateral, sparing the latissimus dorsi muscle, in 25 patients 
and posterolateral, sparing the serratus anterior muscle, in 5 patients.
The study was double-blinded for intervention Groups 1 and 2, and identical 
study medications were prepared by the hospital pharmacy. The hospital pharmacy 
also prepared the computer-generated randomization schedule.
The control group consisted of patients who did not meet the inclusion criteria 
for the study. The control group was included to determine whether persistent post-
thoracotomy pain could be better minimized with an extended, strictly controlled 
pain management protocol than with current standard pain management in the 
clinic. These patients were treated during the same time period as the intervention 
patients. The standard care consisted of TEA with NSAIDs and/or paracetamol, 
followed by oral opioids with NSAIDs after TEA at the hospital and NSAIDs/ 
paracetamol at home. If TEA was contraindicated, the patients were provided with 
IV-PCA. Before the control group patients were discharged, they agreed to fi ll in the 
prospective follow-up questionnaire six months after the surgery. They also granted 
permission to data extraction from the perioperative period. The questionnaires 
used after six months were similar to the ones used for the intervention and control 
patients (Appendix 1). The questionnaires were mailed to 129 control patients, and 
the response rate was 86% (111 patients). 
38
4. MATERIAL AND METHODS
4.3.2. STUDIES III AND V
Study III is a systematic review performed according to the standards described 
in “The Quality of Reporting of Meta-analyses” (QUOROM) statement (208). The 
databases of Medline (from 1966), PubMed, and the Cochrane Central Register of 
Controlled Trials (CENTRAL), were systematically searched for the terms “gabapentin 
or pregabalin or gabapentinoids” or “Lyrica or Neurontin” and “postoperative pain”. 
Additional information on trials were inquired from the Pfi zer Corporation, and the 
30 patients randomized into three groups 
Valdecoxib 40 mg PO (n=10)  
+ temazepam PO 
Diclofenac 75 mg PO (n=10)  
+ temazepam PO 
PCEA (n=10)  
+ temazepam PO  
TEA = thoracic epidural analgesia, PCA = patient controlled analgesia,  ic-block = 
intercostal nerve block, PCEA = patient controlled epidural analgesia  
Thoracotomy 
-PCEA patients: TEA-infusion started at anaesthesia induction  
Parecoxib-infusion 80mg/24h 
for 44h + IV PCA-morphine +  
ic-block 
Diclofenac -infusion 150mg/24h  
for 44h + IV PCA-morphine +  
ic-block  
Ongoing TEA-infusion  
+ PCEA + paracetamol  
 
Valdecoxib 40mg x2 PO +  
IV PCA-morphine  
Diclofenac 75mg x2 PO +  
IV PCA-morphine  
PCA ceases, valdecoxib x2 PO  
continues, oxycodone PO when  
required  
PCA ceases, diclofenac x2 PO  
continues, oxycodone PO when  
required 
TEA-infusion until  
removal of pleural drains,  
then paracetamol replaced  
with ibuprofen +  
oxycodone PO when  
required    
The day of discharge  
-measurements, drug prescriptions,  
  instructions for contacting  
  the study nurse if needed  
Telephone interview 1 week  
Mailed questionnaire 3 and 6 months  
Premedication 
0-point 
2 POD 
 
Removal of pleural drains 
Figure 5. The schedule of Study IV.
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reference lists of reports and reviews were checked. The last study that was included 
was published in September 2006. All randomized, placebo- or active-controlled, 
double-blind human trials were included if they had a minimum of ten patients in 
each study group as recommended by L’Abbe et al. (209). The interventions were a 
treatment with oral gabapentin or pregabalin in any dose during the perioperative 
period. A total of 22 trials of the perioperative administration of gabapentin or 
pregabalin for postoperative pain relief met the inclusion criteria. 
Study V consists of 2 randomized, double-blind cross-over studies with 18 
healthy male volunteers in each. The volunteers in Study 1 were tested twice with 
a period of one week between the test sessions. Heat tolerance was measured using 
a 30 x 30 mm contact thermode that was connected to a participant’s right calf. 
First a measurement was taken of the temperature at which the volunteer reported 
moderate pain (4-6 on a numeric rating scale, NRS of 0-10) was measured by 
increasing the test temperature by 2 degrees at 6-second intervals from 32° to 48°C. 
This target temperature served in the following tests as the volunteer’s individual 
heat stimulus, and the sensation was assessed on an NRS of 0-10. The cold pressor 
test (CPT) was performed by immersing a participant’s right hand in cold water 
(+3°C) for fi ve to ten minutes after the last heat stimulus, and the volunteer assessed 
the intensity and unpleasantness of the pain (0-10) every 15 seconds until he or 
she felt the need to withdraw his or her hand, continuing up to 90 seconds at the 
most. These testing procedures did not induce any tissue injury or infl ammation. 
After the baseline measurements the volunteers were administered 5 mg of 
tropisetron or saline IV in a randomized, double-blind manner, and 30 minutes 
later they received  2 g of paracetamol as an IV infusion. Pain measurements were 
then performed at 30, 60 and 120 minutes after paracetamol was administered. 
All volunteers were given both tropisetron and a placebo in a balanced random 
manner at a week’s interval, repeating the test procedure 2 x 18 = 36 times, and 
the volunteers served as their own control. 
In Study 2, the same 18 volunteers were contacted. Twelve of the volunteers 
participated in the second study and only six new volunteers were recruited. To 
determine pain and sensory in the participants, an electrical pain stimulus was 
induced by  the Pain Matcher, which is  a tool for  pain  autoevaluation that is based 
on the stimulation of the median nerve. The volunteers were instructed to place an 
electrode box located on the table between their fi rst and second fi ngers of their 
dominant hand. Then, a constant stimulation by electric current (10 Hz, 10 mA) 
was provided that intensifi ed the stimulus by successively increasing the pulse width 
from 0 to 450 μs in increments of 7.5 μs, up to a total of 90 steps. This electric current 
halted as soon as the volunteer released his grip, and the value reached (between 0 
to 90 seconds) was saved in the memory of the device. After measuring the baseline 
pain and sensory, the volunteers were administered tropisetron or saline according 
to the same protocol as in Study 1. The measurements were subsequently repeated 
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4. MATERIAL AND METHODS
20 minutes later, and after 30 minutes, 2 g of  paracetamol  was administered 
IV, which was followed by measurements at 30, 60 and 120 minutes after the 
paracetamol had been administered.
The study designs and interventions of all the studies are shown in Table 5, 
and the fl ow charts of the clinical studies (I, II and IV) are presented in Figure 6. 
  Study I Study II Study III Study IV Study V
Participants Elective 
thoracotomy
patients 
(n=111)
Elective 
ambulatory
LCC patients
(n=159)
Surgical 
patients
receiving 
gabapentinoids 
(n=1909)
Intervention 
group: elective 
thoracotomy
patients (n=30); 
Control group: 
thoracotomy
patients not 
eligible for the 
study (n=111)
Healthy male
volunteers
(n=18)
Study 
design
Prospective 
clinical
follow-up 
study, open
Prospective, 
rando-
mized, double-
blind
clinical study
Systematic
review
Intervention: 
prospective, 
randomized, 
partially double-
blind clinical study; 
Control:
prospective clinical 
follow-up study, 
open
2 randomized, 
double-
blind cross-
over studies,
volunteers
Intervention Choice of the 
method
of pain 
treatment by
the 
anaesthetist 
in
charge: TEA/
oxycodone-
PCA/im 
oxycodone;
ibuprofen/
paracetamol 
+
tramadol for 
home
1) Pare/
valdexocib
2) Paracetamol
3) Pare/
valdecoxib + 
dexamethasone
4) Paracetamol 
+ 
dexamethasone
Systematic 
literature
search: 
controlled,
double-blind 
human
trials of 
perioperative
gabapentinoids
(n=22)
Intervention:
1) Diclofenac + 
IV-PCA
2) Pare/valdecoxib 
+ IV-PCA
3) PCEA
Ibuprofen/
paracetamol + 
tramadol for home
Control: standard 
care
Experimental 
studies
(paracetamol, 
tropisetron) 
with cold 
pressor test,
contact heat 
and 
electrical 
stimulation
Collection of 
data
 
Hospital fi les, 
telephone
interview 1 
week after
discharge, 
mailed
questionnaire 
after 3 and  
6 months
 
Data at OR, 
phase 1
and 2 PACU, 
telephone
interview on 
POD 1,
questionnaire 
for PODs
1-7
 
Literature 
search
 
Data at OR, PACU, 
surgical ward 
(Intervention 
patients: 
measurements by
researchers; 
Control patients: 
hospital fi les);
telephone 
interview 1 week 
after discharge
and a mailed 
questionnaire after 
3 and 6 
months 
(intervention), a 
mailed 
questionnaire after 
6 months (control)
Standardized
measurements 
by
researchers
 
LCC=laparoscopic cholecystectomy; TEA=thoracic epidural analgesia; PCA=patient controlled 
analgesia; PCEA=patient controlled epidural analgesia; 
OR=operating room; PACU=postanaesthesia care unit; POD=postoperative day
Table 5. Study designs and interventions
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160 patients randomized
Pare/valdecoxib Paracetamol Pare/valdecoxib+ Paracetamol + 
n=40 n=40 dexamethasone dexamethasone
n=40 n=40
1 drop -out 1 drop -out 1 drop -out
* received * reoperation * received
accidentally due to bleeding, accidentally
dexamethasone, excluded from extra fentanyl,
analyzed from further analyses analyzed from
POD 1 POD 1
Phase 1,2 PACU Phase 1,2 PACU Phase 1,2 PACU Phase 1,2 PACU
analyzed n=39 analyzed n=39 analyzed n=39 analyzed n=40
Home follow-up Home follow-up Home follow-up Home follow-up
7 days, 7 days, 7 days, 7 days,
analyzed n=33 analyzed n=33 analyzed n=33 analyzed n=31
Study II
 
Consecutive thoracotomy patients,
recruited n=114
Analyzed n=111
?TEA n=89
?IV-PCA n=18
?im opioids n=4
Telephone interview 1 week
after discharge (n=111) 
Mailed questionnaire 3 months,
answers n=97
3 drop-outs because of
reoperation
Mailed questionnaire 6 months,
answers n=89
Study I
 
Randomized (n=31)
Allocated to pare/valdecoxib
+ IV-PCA morphine 
(n=10)
Allocated to diclofenac
+ IV-PCA morphine 
(n=10)
Allocated to thoracic
epidural analgesia
(n=10)
No patients lost to follow-up No patients lost to follow-up
Analyzed (n=10) Analyzed (n=10) Analyzed (n=10)
1 drop-out (pare/valdecoxib
group ) due to postoperative
surgical bleeding and
re-operation , replaced with
a new patient
No patients lost to follow-up
Study IV
Figure 6. Flow charts of clinical Studies I, II and IV. POD=postoperative day, PACU= post-anaesthesia care unit
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4. MATERIAL AND METHODS
4.4. OUTCOME MEASURES
4.4.1. STUDIES I AND IV
In Study I (the fi rst thoracotomy study), the primary outcome measure was the 
pain intensity while coughing on POD 1. The patients were measured for their pain 
intensity three times a day on the visual analogue scale (VAS) of 0-10cm (0 = no 
pain and 10 = worst imaginable pain) during rest and while coughing. The following 
factors were then recorded: the cumulative consumption of epidural fentanyl, the 
duration of pleural drainage and postoperative hospitalization, the duration of the 
TEA treatment, the patient satisfaction with the analgesia (scale “good-satisfactory-
poor”), the adverse effects from TEA, and number of patients whose treatment was 
stopped prematurely (for example, due to catheter complications, adverse effects, 
etc.). During a telephone interview one week after discharge, the patients were 
requested to measure their pain during rest and while coughing by using a numeric 
rating scale (NRS). The patients were also asked about other issues, including the 
requirement of analgesics, the adequacy of the prescribed analgesics, their adverse 
effects and their diffi culties in daily life including the disturbances in sleeping due to 
pain. Additionally, a record was made of the number of patients who needed further 
instructions on how to take their pain medication. A mailed questionnaire was 
subsequently sent three and six months after the thoracotomy. This questionnaire 
asked questions regarding the chronic pain that the patients experienced at rest 
and while coughing, the duration of their postoperative pain, their other symptoms 
related to their scar, such as numbness, activities that aggravated their pain, any 
diffi culties they had in daily life and sleep, and their requirement of analgesics 
and other treatment for chronic pain. The patients were also asked to draw the 
localization and nature of their pain in a pain diagram (Appendix 1). 
For Study IV (the second thoracotomy study), the primary outcome when 
comparing the intervention and control groups was the intensity of pain that 
occurred six months after a patient’s surgery. When comparing the intervention 
groups (NSAID groups and PCEA group), the secondary outcomes were the pain 
intensity that the patients experienced while coughing during their fi rst four 
postoperative days. This pain intensity was estimated on the VAS or NRS in the 
PACU. Pain intensity was also measured in terms of the pain intensity at rest 
and during physiotherapy, the consumption of PCA-morphine in Groups 1 and 2, 
the need for rescue medication, and the adverse effects (such as nausea, itching, 
sedation and subjective tiredness) as measured by the VAS. The study patients 
spent the fi rst postoperative night in the PACU, and haemodynamic parameters and 
arterial blood-gases were analyzed. During this time a patient’s pain was measured 
hourly for the fi rst six hours after which the patients could sleep undisturbed. The 
next measurements were obtained by the study nurse in the morning, twice daily 
on the PODs 1-3, and then once per day until discharge. During the PODs 1-4, a 
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physiotherapist also evaluated pain at rest, while coughing, and after standing up. 
The success of physiotherapy was judged on a 0 to 10 scale (0 representing a failure 
of physiotherapy, and 10 indicating very successful physiotherapy).
Hyperalgesia was assessed by two methods. First, after the pleural drains were 
removed, the area of hyperalgesia was tested with a von Frey hair (210). The tested 
area of hyperalgesia was subsequently drawn, scanned and calculated by using pixels 
(area/cm²). Then, “a coughing test” was performed, and the result was defi ned as 
the time needed for the cough-provoked pain intensity to return to baseline.
The study period lasted for the duration of the patient’s hospital stay. Basic 
cardio-respiratory status was recorded twice daily for PODs 1-3, the s-creatinine and 
cystatine-C were followed before and after the operation, and daily urine output was 
measured during two PODs. The duration was also recorded of the hospitalization 
and pleural drainage, and  any incidences of surgical complications were noted. 
All patients in the intervention group were interviewed over the telephone a week 
after being discharged by using a structured questionnaire that was identical with 
that adopted in Study I. This questionnaire asked, for example, about the intensity 
of pain and the drugs taken. The patients’ persistent pain was assessed three and 
six months later by administering a questionnaire that was mailed to the patients. 
This questionnaire was also identical to the one used in Study I (Appendix 1).
In the control group of Study IV, a record was made of the pain treatment 
method (IV-PCA or TEA), the acute pain intensity and consumption of analgesics, 
the adverse effects the patients experienced, and the success of pain management 
during their hospital stay. Six months after the operation, a questionnaire, which 
was similar to the one for the patients in the intervention group, was mailed to 
the control group. 
4.4.2. STUDY II
In Study II (ambulatory LCC patients), the pain experienced at rest and in motion 
and the PONV were assessed in Phase 1 PACU using VAS (0-10 cm) every 20 
minutes, as well as each time the patient requested oxycodone, indicating that the 
pain VAS>3. The time of the fi rst dose of oxycodone was recorded. In Phase 2 PACU 
pain intensity and nausea were assessed at 30-min intervals, and whenever the 
patients requested oral oxycodone. The time of the patient’s discharge from hospital 
was also recorded as well as the number of patients who had to stay unscheduled 
overnight. The patients were requested to fi ll in a questionnaire (Appendix 2) for 
seven PODs, evaluating their pain intensity (VAS) at rest and in motion as well as 
the localization of any pain three times per day, including any pain in the their right 
shoulder. They were also requested to document any additional medication they 
had taken and any adverse effects they had experienced. Additionally, the patients 
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were interviewed over the phone on the fi rst postoperative morning before they 
started to fi ll in the questionnaire.
4.4.3. STUDIES III AND V
Study III is a systematic review on perioperative gabapentinoids. The following 
data were extracted in this study: publication details, patient population, number of 
patients, age, gender, surgical procedure, description of intervention, study design, 
duration and follow-up, intraoperative and postoperative analgesics, outcome 
measures, analgesic outcome results, withdrawals, and adverse effects. In addition, 
the sources of funding were checked to determine whether the trial was sponsored 
by the pharmaceutical industry and whether this was reported, as recommended by 
the CONSORT statement (211). The quality of the study (randomization/ allocation 
concealment, blinding measures, withdrawals and drop-outs) was evaluated using 
the Oxford Quality Scale (212), and the validity was examined using the Oxford 
Pain Validity Scale (213). 
The main outcome measures were the pain scores, the total analgesic consumption 
for the fi rst 24 hours, and the treatment-related adverse effects. The difference 
in pain intensity between the control and gabapentin groups was calculated by 
deducting the pain intensity in the treatment group from the value in the control 
group at different times. The number-needed-to-treat (NNT) was then calculated 
for the reduction of the adverse effects (nausea, vomiting, urinary retention) that 
were caused by gabapentin as compared to the placebo, and the number-needed-to-
harm (NNH) was also calculated for the increase in sedation and dizziness during 
the 24-h follow-up after a single 1200 mg dose of gabapentin that was administered 
preoperatively (5 studies).
The fi rst part of Study V (an experimental study with healthy volunteers) 
included the following primary outcome measures: the individual change in pain 
intensity (NRS 0-10) produced by the individually tested heat stimulus that provoked 
moderate pain at baseline, the individual change in cold pain intensity (NRS), cold 
pain tolerance (seconds) and cold pain unpleasantness (NRS). In the second part 
of the study, an electrical pain stimulus (Pain  Matcher)  was used. The primary 
outcome measures were the sensory threshold (time in seconds when the electrical 
pulses began to be detected), the pain threshold (when the pulses started to feel 
painful) and the moderate pain intensity (NRS 4-6/10). A literature search was 
conducted and an analysis was made for the human experimental pain models 
concerning the analgesic effects of paracetamol, and a review was made of all animal 
and human studies on the interactions of paracetamol and 5-HT3-antagonists. 
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4.5.1. POWER ANALYSES
A power analysis was conducted in Studies II, IV and V. Study I was a prospective 
follow-up study without randomization, and Study III was a systematic review. 
In Study II, the sample size estimation was based on the hypothesis that a 25% 
reduction in opioid consumption by parecoxib and paracetamol would be clinically 
signifi cant (71, 82), and the average pain intensity after LCC was extracted from the 
studies by Alponat et al. (214) and Aubrun et al. (215). After calculation, 32 patients 
per group were needed when the α error equalled 0.05 and the power equalled 90%. 
The sample size in Study IV was estimated for the NSAID + IV-PCA morphine 
versus the TEA with reference to Study I, in which the primary outcome measure 
was the pain intensity while coughing on POD 1. At least 23 patients per group were 
required when the α error equalled 0.05 and the power equalled 80% (a change 
in VAS of 2/10 with a SD of 2.3). In Study V/part 1, the sample size estimation 
was based on the assumption that the baseline level of pain induced by the heat 
stimulus is NRS 5 (SD 2), which is reduced to NRS 3 (SD 2) by paracetamol, and 
tropisetron abolishes its analgesic action completely (NRS 5, SD 2). Therefore, the 
adequate sample size would be 15.8 volunteers per group when the α error = 0.05 
and the power = 80%. In Study V/part 2, it was assumed that the baseline level 
of pain induced by the intensifying electrical stimulus (tolerance in seconds) without 
medication is 25 s (SD 10). Paracetamol reduces that to 15 s (SD 10) and tropisetron 
completely abolishes the analgesic action of paracetamol (25 s, SD 10) (29, 30). 
Eighteen volunteers per study group were recruited in these two cross-over studies.
4.5.2. STATISTICAL METHODS
The descriptive data were presented as the mean + SE (standard error, Study II) or 
the mean (SD, standard deviation) and the range, or as the actual numbers where 
appropriate. The P<0.05 was considered to be statistically signifi cant in all studies. 
Study I compared the pain intensity on the day of discharge and the total cumulative 
consumption of epidural fentanyl using the Student’s t-test (unpaired, two-tailed). 
In Study II, a statistical analysis was conducted of the demographic data and 
the single effi cacy end points, and the one-way analysis of variance (ANOVA) was 
used. For the pair-wise comparisons, Bonferroni-corrected contrasts were used. 
The VAS scores for pain were treated as continuous parametric data and they were 
tested using ANOVA. The Kruskall-Wallis test was applied to the non-parametric 
data, such as the time until the fi rst oxycodone dose and the amount of oxycodone 
needed. In addition, a Chi-square test was used to compare the number of patients 
that needed additional analgesics. These analyses were performed using NCSS for 
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Windows (version 2000). Study IV did not reach the intended sample size (see 
5.1. Results), and consequently, primarily descriptive methods of analysis were 
adopted. Other analyses included the non-parametric methods, such as the Sign 
test and the Wilcoxon matched pair signed-rank test, the cross-tabulations with 
the chi-square test of independence and Fisher’s exact test for statistical analyses. 
Parametric methods (Student’s t-test and correlations) were adopted for the 
comparisons between the intervention patients and the control patients. 
In Study V/part 2, the pain and sensory scores at each point in time were 
also expressed as a percentage of the individual score reported at baseline, which 
was calculated according to the following formula: Pain score = the pain detection 
threshold at the t(x) x 100/pain detection threshold before treatment (t0) (29). The 
sensory and moderate pain scores were then calculated equally. The variation in 
the pain measurements that were produced by tropisetron or by the placebo is a 
normally distributed continuous variable, and the differences between the groups 
were calculated using a repeated-measures ANOVA. To calculate the statistical 
analyses, a Prism4 for Macintosh (GraphPad Software Inc, La Jolla, CA) was utilized. 
Study III concentrated on the quantitative analysis of the opioid consumption in 
the studies where a single, preoperative dose of gabapentin was administered, where 
the duration of the postoperative observation was at least 24 hours, and where the 
opioid consumption data were expressed as means, with an indication of variance. 
The consumption values of fentanyl and tramadol were scaled to arbitrary “morphine 
equivalent” units, using the conversion factors 100:1 and 10:1, respectively. The 
meta-analysis was calculated with the Comprehensive Meta-Analysis programme 
(version 2.2.027, Biostat, Englewood, NJ). The random effects model was selected 
to combine the materials that were based on the clinical heterogeneity that occurred 
across the individual studies, assuming a common among-study variance component 
across the subgroups. An analysis was then conducted using a metaregression to 
determine the possible dose-response on the opioid sparing effect of a single-dose 
of 300-1200 mg of gabapentin preoperatively for the fi rst 24 hours. The pooled raw 
data method was subsequently used to calculate the NNT and NNH.
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5.1. CHARACTERISTICS OF THE PATIENTS AND PROCEDURES IN 
STUDIES I, II AND IV
In Study I, three patients were excluded from the analysis due to their re-operation 
within a week after their fi rst thoracotomy. Accordingly, the fi nal number of patients 
included was 111. In Study IV, the intended sample size was not reached in the 
intervention group due to the global withdrawal of valdecoxib (73), and at the same 
time, thoracoscopic operations were replacing many open thoracotomies. Thus, the 
study was terminated after 30 patients had completed it, which was the size of one 
block in the randomization. NAM provided us a special permission to continue the 
study until 30 patients, presuming strict exclusion criteria concerning cardiovascular 
diseases. One patient from the valdecoxib group was withdrawn due to surgical 
bleeding and a re-operation and that patient was replaced with a new patient.  In 
the intervention group, twenty-one patients (70%) had a malignant disease and nine 
patients had a benign disease (30%), and this difference was signifi cant (p<0.01). 
Ninety-two of the 111 control group patients had a malignant disease (83%) and 19 
patients had a benign disease (17%) (p<0.01). For details, see Table 6.
In Study II, 160 patients were recruited and 1 patient was excluded from the 
paracetamol group due to bleeding and re-operation. Out of the 159 patients who 
were initially scheduled for day-case LCC, 8 patients (5%) had to stay overnight in 
hospital. The reasons for this were postoperative pain (one patient), PONV (four 
patients), a surgeon’s wish to observe the bleeding (two patients), and cardiac 
arrhythmias (one patient). For details, see Table 6.
The most common pre-surgery diagnoses in Study I were cardiovascular disease 
in 30% of the patients and respiratory disease (for example, bronchial asthma, 
COPD) in 14% of the patients. Other issues were musculoskeletal, endocrine (for 
example, hypothyreosis and diabetes), neurologic and psychiatric (including alcohol 
abuse). Fifty patients (45%) did not have a primary diagnosis. In the intervention 
group of Study IV, 13 patients (43%) had cardiovascular disease, 6 (20%) had 
respiratory disease, 3 (10%) had endocrine disease, and 1 (3%) had epilepsy. Eight 
(27%) patients had no pre-existing diagnosis. In the control group, 68% of the 
patients suffered from cardiovascular diseases, 35% from respiratory disease and 
15% from endocrine disease; 20% had no pre-existing diagnosis. In the intervention 
study, a signifi cant cardiac disease was a contraindication. In Study II, 13 patients 
(8%) had mild cardiovascular disease (hypertension or occasional arrhythmias), 
7 (4%) had hypothyreosis and 25 patients (16%) had some other minor health 
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problems. The rest of the patients in the Study II (120 patients, 75%) were healthy, 
not including gall bladder disease.
The types of the operations in Studies I and IV are presented in Figure 7. Out of 
the 111 operations in Study I, 19 (17%) were emergency operations. Similarly, out of 
the 111 operations in Study IV (control group), 13 (12%) were emergency operations. 
  Study I (n=111)
Study II
(n=159)
Study IV/
Intervention 
group
(n=30)
Study IV/
Control 
group
(n=111)
Male/Female (%) 62/38 25/75 43/57 45/55
Age, years, mean (SD) 54 (15) 42 (2) 61 (9) 60 (11)
BMI, mean (SD) 26 (2) 25 (0,5) 25 (3) 26 (2)
ASA status (%)
I 24 75 13 3
II 28 25 40 9
III 41 0 33 78
IV 7 0 14 10
Malignant/benign disease (%) 65/35 0/100 70/30 83/17
Duration of the operation,
min, mean (range) n.a. 54 (45-61) 156 (71-256) 132 (66-220)
Blood loss during the 
operation, ml, mean (SD) 320 (210) 50 (15) 240 (174) 220 (164)
BMI=body mass index, n.a.=not applicable
Table 6. Summary of the demographic and clinical data of patients in studies I, II and IV.
 
 
a)
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Figure 7. Types of operations (%) in Study I (a), Study IV Intervention group (b) and Study IV Control 
group (c). Some patients had several procedures during the same surgery and only the main procedure 
is considered here.
b)
c)
5.2. CHARACTERISTICS OF ANALGESIA IN THORACOTOMY 
STUDIES I AND IV
A vast majority of the thoracotomy patients were treated with thoracic epidural 
analgesia in Study I as well as in the control group of Study IV, whereas only 
one-third of the intervention patients in Study IV received TEA. The duration of 
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Study I
(n=111)
Study IV/
Intervention group
(n=30)
Study IV/Control 
group
(n=111)
TEA/iv-PCA opioid/other treatment 89/18/4 (80%/16%/4%)
10/20 
(33%/67%)
104/7
(94%/6%)
Placement of the epidural catheter Th 4/5 - 7/8 Th 4/5 - 6/7 Th 4/5 - 8/9
Duration of TEA/iv-PCA (days) 5(2) 6(2) 4(2)
Removal of pleural drains (POD) 5(3) 5(3) 4(2)
Day of discharge (POD) 8(4) 8(3) 5(2)
Patients’ satisfaction with pain management*
      treatment was good 87% 100% 90%
      treatment was satisfactory 13% 0% 10%
      treatment was poor 0% 0% 0%
TEA treatment stopped prematurely 
(total)** 24% 0% 20%
      catheter slipped out or did                             
      not work 20% 0% 16%
      adverse eff ects 4% 0% 4%
TEA=thoracic epidural analgesia, PCA=patient controlled analgesia, POD=postoperative day.
Mean (SD) or actual numbers given when appropriate.
* In the intervention group patients’ satisfaction was assessed with NRS 0-10, and ”treatment 
was good” was equivalent to NRS 8-10/10. 
** In the intervention group a new epidural catheter was placed in 1 patient due to the original 
catheter slipping out.
Table 7. Characteristics of perioperative analgesia in thoracotomy Studies I and IV.
the invasive pain management (TEA or IV-PCA) was signifi cantly longer for the 
intervention group patients (Study IV) who were involved in the strict study protocol 
in comparison to the non-randomized patients in Study I and to the standard care 
patients (control group) in Study IV (p<0.05). However, the duration of the pleural 
drainage was similar for the groups. The control patients in Study IV were discharged 
signifi cantly earlier than both the intervention patients (Study IV) and the patients 
in Study I (p<0.001). Furthermore, all patients reported being satisfi ed with their 
pain management. One-fi fth to one-fourth of the patients who were not involved in 
the controlled pain management protocol (Study I and Study IV/control group) lost 
their TEA prematurely due to technical problems or to adverse effects, whereas this 
was not a factor for the patients in the intervention group. For details, see Table 7. 
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5.3. PAIN IN THE ACUTE PHASE (STUDIES I, II AND IV)
The pain intensity (VAS or NRS) from the PACU to one week after the patient’s 
discharge is presented in Figure 8. During the early postoperative phase in Study 
I, the pain intensity with the IV-PCA patients was NRS 5.7/10 compared to TEA 
patients whose mean NRS was 4.9/10. The NSAID groups in Study IV were 
combined because the analgesic effi cacy was similar between valdecoxib and 
diclofenac. In comparison, the post-physiotherapy pain on POD 1 was signifi cantly 
less in the epidural group versus the NSAID group (VAS 2.9 versus 5.0, respectively) 
(p<0.05), and physiotherapy was more successful on POD 3 for the epidural patients 
(p<0.05). Furthermore, the duration of the provoked pain after coughing was 
longer in the NSAID group than the epidural group. However, the patients in the 
intervention group who participated in the Study (n=30) and the patients in the 
control group (n=111) displayed no signifi cant differences in their pain intensity 
during hospitalization. Half of the intervention patients (16/29) had a measurable 
area of hyperalgesia in hospital without differences between the subgroups. The 
patients with hyperalgesia also experienced signifi cantly more pain when coughing 
in the PACU and on POD 3. 
APS was available fi ve days a week for the control patients whereas the intervention 
patients were seen by the researchers for seven days a week. Furthermore, the control 
patients did not have the opportunity for close follow-up after discharge other than 
included in the standard care.  
The natural course of pain intensity after ambulatory LCC (Study II) is presented 
in Figure 8.  No differences were evident in the pain intensity between the four groups 
at home. Pain in the right shoulder was a complaint expressed by 30-36% of the 
patients at home, and it was most intense on POD 1 and continued for several days. 
Approximately 30% of the thoracotomy patients in Study I had diffi culties in 
their daily activities due to their postoperative pain a week after being discharged 
from hospital. In Study IV, no signifi cant difference in the pain intensity was 
detected between the NSAID and TEA groups. Out of the 30 patients, pain disturbed 
the daily activities of 7 patients (23%), and 14 patients (47%) had diffi culties in 
sleeping due to their pain. 
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Figure 8. Pain intensity (VAS/NRS 0-10) at rest (a) and in motion (b) in studies I, II and IV. Mean (SD) are 
given. PACU=postanaesthesia care unit at 3-4h, LCC=laparoscopic cholecystectomy, TEA=thoracic epidural 
analgesia, thorac=thoracic surgery, POD=postoperative day (assessed in the afternoon), discharge=day when 
the patient was discharged from hospital (the day of surgery in day-case LCC patients), 1week=1 week after 
discharge. **= not applicable. One week information was collected from thoracotomy patients by phone 
and from LCC patients by a questionnaire.  * = On POD 4 the TEA patients in study IV had signifi cantly 
more pain when coughing compared to NSAID and Control patients (p<0,05).
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5.4. CONSUMPTION OF ANALGESICS IN THE ACUTE PHASE 
(STUDIES I, II AND IV)
5.4.1. IN HOSPITAL
In Study IV, the IV-PCA opioid consumption was similar in the diclofenac and 
coxib groups [mean (SD) were 35 mg (12) and 34 mg (13) per day, respectively]. 
Furthermore, there were no differences in a need for supplemental oxycodone after 
PCEA/PCA. Most of the patients in the control group (94%) had TEA, and all of 
them were administered NSAIDs or paracetamol, or both. Additionally, half of the 
patients needed regular weak opioids after TEA/PCA. 
In the management of pain after ambulatory LCC in Study II, paracetamol 
was as effective as pare-/valdecoxib. The time until the fi rst dose of oxycodone in 
Phase 1 PACU was similar in the four groups (mean 14 minutes, SD 2), as was the 
total amount of oxycodone required (mean 12 mg, SD 1). Dexamethasone decreased 
the need for oxycodone in Phase 2 PACU just prior to discharge, but this opioid-
sparing effect was similar in both paracetamol- and coxib-treated patients. The mean 
oxycodone consumption was 9.1 mg (SD 1.0) in the groups without dexamethasone 
as compared to 7.0 mg (SD 1.0) in the groups with dexamethasone (p<0.05). 
5.4.2. DURING THE FIRST WEEK AT HOME
In Study I, during the fi rst week at home after being discharged 92% of the patients 
required analgesics daily. Ibuprofen 600 mg or paracetamol 1 g was taken regularly 
three times a day by 86% and tramadol 100 mg three times a day by 71% of the 
patients. Sixteen per cent of the patients needed renewed prescriptions of analgesics 
since the original amount was not deemed to be suffi cient. One- fi fth of the patients 
needed instructions on how to take pain medication a week after discharge, and 
the same percentage of patients phoned the APS nurse when they encountered 
problems with pain. Furthermore, one patient in ten felt that the change from 
epidural to oral pain treatment was too dramatic and that they were discharged 
prematurely while they still had unacceptable pain. When comparing the control 
patients with the intervention patients in Study IV, only 23% of the control patients 
were prescribed weak opioids with NSAIDs/ paracetamol for home, whereas 100% 
of the intervention patients received them. Moreover, one week after discharge, 
77% (23/30) of the intervention patients needed weak opioids daily in addition 
to NSAIDs, and 23% (7/30) patients needed a renewed prescription for tramadol 
(versus 71% and 16% in Study I, respectively). 
Signifi cantly more patients in Study II in both the coxib-treated groups 
(Groups 1 and 3) needed additional rescue analgesics on POD 1 and POD 4 than 
the patients who were given paracetamol (p<0.01 on POD 1 and p<0.05 on POD 
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4). Subsequently, however, that difference receded. Almost half of the LCC patients 
still required some type of analgesic medication one week after being discharged, 
but no one needed weak opioids.
5.5. PERSISTENT PAIN AFTER THORACIC SURGERY 
(STUDIES I AND IV)
Figure 9 represents the intensity of post-thoracotomy pain and the impact it has 
on daily life and sleep three and six months after thoracic surgery. 
5.5.1. THREE MONTHS AFTER THORACOTOMY
Study I found that at 3 months, 8 TEA-patients (11%) and 4 PCA-patients (29%) 
experienced disturbing chronic pain (see the defi nition in Figure 8), and 40% of 
the patients in both groups were completely free of pain. The reported pain was 
predominantly tenderness or aches, but numbness (45%), burning pain (10%) and 
lancinating pain (2%), as signs of possible intercostal neuralgia were also detected 
Furthermore, when patients with or without persistent pain were compared three 
months after surgery, there was no signifi cant difference in the pain intensity on 
the day of discharge between the groups. Instead, the cumulative consumption 
of epidural fentanyl was somewhat higher on PODs 1-3 in the patients who had 
persistent pain at 3 months (P=0.06) when compared to those who were free of 
pain. In Study IV, at 3 months, half (15/30) of the intervention group patients 
still needed daily analgesics.
5.5.2. SIX MONTHS AFTER THORACOTOMY
In Study I, 7 (12%) of the TEA patients and 3 (23%) of the IV-PCA patients 
experienced persistent pain 6 months after the thoracotomy. One patient reported 
severe pain, none of the patients had excruciating pain. Out of all patients, 21% 
were taking analgesics daily and 15% on a weekly basis. Weak opioids were needed 
by 20% of the patients as long as 6 months after the thoracotomy. Seventeen per 
cent of the patients had experienced pain for less than 3 weeks, 17% from 3 weeks 
to 2 months, and 16% from 2 to 5 months. 
In Study IV, persistent pain 6 months after the thoracotomy was more common 
in the control patients than in the patients in the intervention group (24% versus 
3%, respectively) (p<0.001). Out of the 111 patients, 25 patients in the control group 
(25%) needed daily analgesics compared to 2 (7%) out of the 30 patients in the 
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Figure 9. Mean intensity (SD) of persistent pain at 3 and 6 months expressed as NRS/VAS (a) and 
incidence of persistent pain (%) which disturbs daily life and sleep (b) (Studies I and IV). NRS=numeric 
rating scale 0-10; VAS=visual analogue scale 0-10; Intervention=intervention group in Study IV (NSAID 
group + epidural group, n=30); Control=Control group in Study IV (standard care patients, n=111). In Study 
I only patients treated with epidural analgesia are involved in the fi gure (n=73 at 3 months and n=65 at 
6 months). Chronic pain was defi ned as VAS/NRS>3/10 and as “moderate”, “severe” or “excruciating” on 
the verbal rating scale (VRS), and  it disturbed daily life and/or sleep.
 ** ** 
a)
b)
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intervention group (p<0.001). Twenty-one patients in the control group needed 
weak opioids and four needed strong opioids, which were prescribed to three patients 
with benign disease. No one in the intervention group needed opioids at this time 
point. Furthermore, in those control patients who developed persistent pain, their 
pain was signifi cantly more intense when coughing on POD 3 (mean VAS 4.1, SD 
2.0). Hyperalgesia did not, however, predict prolonged pain. The only patient with 
persistent pain at 6 months (the coxib group) had a considerably longer duration 
of pain after coughing (60 seconds on POD 3) than other intervention patients 
(median 2 seconds, range 0-6). 
5.6. ADVERSE EFFECTS (STUDIES I, II AND IV)
The adverse effects in the clinical Studies I, II and IV are presented in Table 8. 
Among all the thoracotomy patients in Studies I and IV, two patients in Study IV/
control group with epidural treatment had severe respiratory depression and needed 
mechanical ventilation. No differences emerged in Study IV between the parecoxib 
or valdecoxib, diclofenac and epidural groups regarding their cardiorespiratory, 
bowel and urinary functions, diuresis, blood loss, creatinine and cystatine-C levels.
Table 8. Adverse eff ects in Studies I, II and IV.
Adverse eff ect Study I/TEA
Study I/
PCA
Study IV/
Int., TEA
Study 
IV/Int., 
NSAID+PCA
Study 
IV/Control Study II
Nausea1 15% 28% 10-30% 10-25% 18% 3%
Tiredness2 n.a. n.a. 40-45% 30-45% 24% n.a.
Dizziness/
drowsiness 4% 11% n.a. n.a. n.a. 7%
Pruritus 13% 0 30% 5% 17% 0
Hypotension3 2% 0 0 0 5% 0
TEA=thoracic epidural analgesia; PCA=patient controlled analgesia; Int.=Intervention group; 
n.a.=not applicable. Studies I and IV=thoracotomy patients; Study II=day-case LCC patients.
1 Needed medication for nausea; all of these patients in the control group had epidural 
analgesia; Diff erences between IV/intervention vs. IV/control groups and between NSAID+PCA 
vs epidural patients=NS; LCC patients who suff ered from nausea needed to stay
overnight in hospital.
2 NRS>5/10; all of these patients in the control group had epidural analgesia.
3 Hypotension which needed adjustment of treatment or medication.
5.7. RESULTS OF STUDY III 
This systematic review included a total of 22 randomized, controlled, double-blind 
clinical trials of the perioperative administration of gabapentin or pregabalin for 
postoperative pain relief. The total number of patients was 1 909, of which 786 
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received gabapentin (21 studies) and 99 received pregabalin (1 study). The patients’ 
ages ranged from 18 to 74 years, 1 265 were women and 509 were men. 
The doses of gabapentin administered to the patients were 300-1200 mg and 
for the pregabalin study, the doses were 50 mg or 300 mg. A single dose was 
administered in 13 studies and multiple doses were administered in 9 studies. The 
duration of the trials ranged from 4 hours to 10 days. In the only trial with pregabalin, 
the drug was administered postoperatively after dental surgery, and regarding the 
patients’ satisfaction with their pain relief and duration of analgesia, 300 mg of 
pregabalin was determined to be more effi cient than 400 mg of ibuprofen. 
5.7.1. ANALGESIA
The pain relief was signifi cantly better in the gabapentin groups than in the control 
groups. For the different types of surgery, the difference in pain intensity varied 
widely between the control and gabapentin groups at rest and in motion during the 
fi rst 24 hours after a single 1200 mg dose of gabapentin administered 1-2 hours 
preoperatively, and the pain intensity difference was greatest after a discectomy 
and a hysterectomy. The time for the fi rst analgesic request was reported in 5 of 
the 22 studies, and 2 of these studies detected a difference that favoured 1200 mg 
of gabapentin over the placebo. 
After a single preoperative dose of 300-1200 mg of gabapentin, the opioid-sparing 
effect during the fi rst 24 hours ranged from 20% to 62%. A meta-analysis revealed 
that the combined effect of a single dose of gabapentin on opioid consumption 
was equivalent to a reduction of 30+4 mg in morphine (mean+95% CI) consumed 
during the fi rst 24 hours postoperatively. Figure 3/Study III displays the weighted 
mean differences (WMDs) with the 95% CI and the combined effect of gabapentin 
on the patients’ opioid consumption. Whereas the heterogeneity among the studies 
was signifi cant, it was not due to the dose of gabapentin. 
When the administration of gabapentin continued two to ten days after surgery, 
fi ve trials reported long-term effects. The follow-up ranged from one to six months. 
Three studies concentrated on abdominal hysterectomies and two on mastectomies. 
For acute pain, four of the fi ve studies favoured gabapentin to the placebo, and two 
of these studies found a difference in chronic pain, whereas the other two did not.
5.7.2. ADVERSE EFFECTS
After a single dose of 1200 mg of gabapentin was administered 1-2 hours 
preoperatively, the numbers-needed-to-treat (NNT) to prevent nausea, vomiting or 
urinary retention during 20-24 hours after surgery, were 25, 6, and 7, respectively. 
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The numbers-needed-to-harm (NNH) for gabapentin to produce excessive sedation 
or dizziness were 35 and 12, respectively. No signifi cant differences in other adverse 
effects were reported.
5.7.3. ANXIOLYTIC EFFECTS
Two trials analyzed the anxiolytic properties of gabapentin. In one study, 
premedication with gabapentin produced signifi cantly lower preoperative VAS 
anxiety scores than the placebo (212). The second study determined that 15 mg 
of oxazepam was more effective in relieving preoperative anxiety than 1200 mg of 
gabapentin (217).   
5.8. RESULTS OF STUDY V
The baseline measurements in this experimental study were similar between the 
sessions and the study groups. In Study 1, paracetamol 2 g IV did not produce any 
statistically signifi cant analgesic effects in either the patients’ heat or cold pain 
intensities or in their cold pain tolerance. In Study 2, paracetamol alone did not 
produce any differences in sensory, pain detection or in the moderate pain thresholds 
of the electrical stimulus with Pain Matcher. However, when the percentage scores 
were calculated according to Pickering et al. (29), an analgesic effect was detected 
for the combination of paracetamol and tropisetron (Figure 3/Study V). This means 
that contrary to Pickering’s fi ndings, tropisetron seemed to amplify the analgesic 
action of paracetamol. Nonetheless, conclusions concerning any possible interaction 
between paracetamol and tropisetron cannot be drawn based on these volunteer 
studies.
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This thesis evaluated the intensity of acute post-thoracotomy pain and the incidence 
of chronic pain after thoracic surgery in two studies, including the possibilities of 
managing pain in the acute phase as well as in the sub-acute phase at home. To 
prevent acute and persistent post-thoracotomy pain, the extended protocol for the 
high quality pain management in hospital, also covering the fi rst week at home 
after the patient’s discharge, was found to be more signifi cant than any particular 
analgesic technique in itself. The importance of a strict pain management protocol 
was also observed after ambulatory LCC in the acute phase. This was an antiemetic 
anaesthetic technique that involved multimodal pain treatment with NSAIDs/
paracetamol + corticosteroids as opioid-sparing analgesics that enabled 95% of 
the patients to be discharged on the day of surgery. In addition, the opioid-sparing 
and pain alleviating role of the gabapentinoids in the acute postoperative phase was 
demonstrated in a systematic review. According to an experimental volunteer study, 
the previously suggested interaction in which tropisetron abolishes the analgesic 
action of paracetamol, could not be investigated due to the lack of a measurable 
analgesic effect of paracetamol.
6.1. SELECTING THE RIGHT METHOD OF PAIN MANAGEMENT
Several factors infl uence the evaluation of the best method for postoperative pain 
management. For example, invasive methods (neuraxial blocks with catheters, IV-
PCA) are strongly recommended after very painful operations, such as a thoracotomy 
(47, 50, 100, 101, 103, and Studies I & IV), and in the surgery of the upper abdomen. 
However, patients who undergo day-case surgery do not particularly benefi t from 
invasive methods, as these would increase the time and costs of their perioperative 
care, not to mention the risk of side-effects. Instead, multimodal pain management 
utilizing adjuvant analgesics, such as dexamethasone can be warmly recommended 
especially in day-case LCC (136, Study II). Table 9 lists the factors that need to be 
considered when determining the best method of pain management for an individual 
patient.
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6.2. ACUTE AND PERSISTENT POST-THORACOTOMY PAIN
6.2.1. TRANSITION FROM ACUTE TO CHRONIC POSTSURGICAL PAIN
The progression from acute to chronic pain is a complex phenomenon, involving 
an association with various risk factors that are surgical, psychosocial, socio-
environmental and patient-related, as well as the known polymorphisms in human 
genes (4, 5, 179; Table 4). Postoperative pain consists of pain that is somatic, 
infl ammatory, neuropathic and visceral, and it triggers a stress response that 
activates the central nervous system. Local tissue injury also leads to the spontaneous 
fi ring of nociceptors and their increased sensitivity to stimuli (primary hyperalgesia). 
This continued input from the perioperative noxious injury barrage by severe acute 
pain may lead to changes in the central nervous system, resulting in sensitization 
and pain from a wider area (secondary hyperalgesia). This phenomenon is a dynamic 
refl ection of the central neuronal plasticity, “a pain memory”, which is considered to 
be the basis for chronic postsurgical pain. These long-term neurobiological changes 
occur rather rapidly, even within hours of an acute injury (174, 178). However, most 
Patient related factors
 
Age
BMI (sleep apnoea, technical diffi  culties
in placing epidural catheters, etc.)
Risk factors for chronic post-surgical pain
(see Table 4)
Anticoagulation, other medications
(e.g. long-term opioid use)
Preference of the patient
Factors related to the type of 
surgery
 
Major/minor surgery
Thoracoscopic/open thoracotomy
Laparoscopic/open abdominal surgery
Upper/lower abdomen
Orthopaedic surgery and mobilization
Risk of nerve damage
Patient monitoring possibilities
 
PACU/ ICU/ surgical ward
APS
APS follow-up outpatient clinic
Time of discharge from hospital
 
Day-case surgery
Fast-track surgery
Longer hospitalization
BMI=body mass index; PACU=postanaesthesia care unit; ICU=intensive care unit; 
APS=Acute pain service
Table 9. Factors infl uencing the choice of the method of postoperative pain management.
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of the analgesics that are used to alleviate postoperative pain are not very effective 
for secondary hyperalgesia. 
Most clinical studies on acute postsurgical pain have focused primarily on the 
acute phase when patients are still in hospital. However, few studies provide data 
on the sub-acute phase when patients are at home recovering and are rehabilitating 
from surgery. During this phase, central sensitization continues, bridging the 
transition from acute to persistent postoperative pain. Two thoracotomy studies 
in this thesis (I, IV) offer some information regarding the pain and the condition 
of the patients one week after being discharged from hospital. 
6.2.2. MANAGEMENT OF ACUTE PAIN AFTER THORACOTOMY IN STUDIES I AND 
IV
During the time between Studies I and IV, thoracic epidural analgesia has been 
established in the management of acute pain after thoracotomy. In the beginning 
of the 21st century (Study I), 80% of the patients were treated with TEA, 16% with 
IV-PCA and 4% with conventional methods, such as a single-shot intercostal nerve 
block and  intramuscular oxycodone, and NSAIDs/paracetamol as basic medication. 
At the end of the past decade (Study IV), however, 94% of the patients had TEA and 
6% IV-PCA. This indicates that conventional “low-tech” methods were no longer 
acceptable due to their inferior effi cacy in pain management. 
Thoracic epidural analgesia has demonstrated its superiority in both thoracotomy 
studies, particularly in the treatment of dynamic, evoked pain. This fi nding is 
consistent with recent literature (see Thoracotomy 2.3.1.). Physiotherapy was also 
more successful in the epidural group, and the duration of pain after coughing was 
shorter (Study IV). One unexpected outcome was that the pain treatment in all the 
intervention groups provided suffi cient analgesia for physiotherapy.
6.2.3. PERSISTENT POST-THORACOTOMY PAIN IN STUDIES I AND IV
In the two thoracotomy studies, the incidence of chronic pain 6 months after surgery 
was somewhat lower than described in the literature, ranging from 3% to 24% 
as compared to the usual incidence of 5-65%. According to the fi rst thoracotomy 
study, 12% of the TEA patients and 23% of the IV-PCA patients had disturbing 
pain 6 months after surgery. This comparison of methods was not possible in the 
second thoracotomy study because only 1 patient in the intervention group (coxib 
+ IV-PCA) had chronic pain after 6 months, compared with 24% of the patients 
in the control group. 
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According to Studies I and IV, the combination of thoracic epidural analgesia 
and extended postoperative pain management at home may decrease the occurrence 
of chronic post-thoracotomy pain. Some evidence suggests that TEA could prevent 
central sensitization, but this fi nding remains controversial (11, 155). Blocking the 
neuronal pathway during surgery with epidural local anaesthetics does not decrease 
humoral biochemical responses (for example, prostaglandin E2 and interleukins), 
which must be inhibited by systemic analgesics (218). In a meta-analysis conducted 
by Bong et al. (197), pre-emptive TEA appeared to reduce the severity of acute 
pain without any effect on the incidence of chronic pain. By contrast, in Study 
IV, those patients who had hyperalgesia also had more pain when coughing. 
However, conclusions cannot be drawn regarding whether hyperalgesia could 
predict persistent post-thoracotomy pain, as only one patient in the intervention 
group had persistent long-term pain. 
In the prevention of acute as well as persistent post-thoracotomy pain, it is 
possible that the continuous high quality patient care in the acute phase covering at 
least the fi rst week at home could be more signifi cant than any particular analgesic 
method per se. However, it is important to ensure that the effective preventive 
analgesic regimen is continued into the sub-acute phase in the post-discharge period. 
This means for as long as the nociceptive input from the wound area persists after 
surgery – approximately 4-6 weeks postsurgery. This phenomenon has also been 
suggested after hip or knee replacement surgery, where the superior analgesic 
regimen and follow-up after discharge also reduced chronic pain when compared 
to standard-of-care analgesia (219). After thoracotomy, eight per cent of patients 
had neuropathic pain in the immediate postoperative period in hospital, but this 
proportion was increased to 22% after 3 months (220). If the patient continues to 
have moderate to severe pain on the day of discharge, neuropathic features of pain, 
and needs several different pain medications, the anaesthesiologist should follow-
up after 1-3 weeks by phone or by appointment in order to recognize the patients 
who need further treatment (221). This type of experimental “post-surgery APS 
follow-up outpatient clinic” has recently been established at the Helsinki University 
Central Hospital. 
6.2.4. WHAT IS THE BEST ANALGESIC METHOD FOR THORACOTOMY PATIENTS?
The role of thoracic epidural analgesia as the gold standard in acute post-
thoracotomy pain is slowly diminishing. The reason for this decrease in usage is 
that it is a technique that is invasive, costly and labour-intensive, and the rare but 
potentially disastrous complications (epidural hematoma and abscess) cannot be 
ignored (222). There is no doubt that with functioning TEA, the pain relief can be 
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excellent, but the risk for adverse effects compared with the benefi ts of this invasive 
technique should be carefully considered in low-risk patients. 
IV-PCA with strong opioids, combined with NSAIDs/ paracetamol and single-
shot intercostal nerve blocks with local anaesthetics, offers acceptable pain relief 
after thoracotomy, especially at rest (Studies I and IV). High-risk patients who 
suffer from pulmonary and cardiac disease and/or massive obesity with sleep 
apnoea were excluded from these studies. Altogether, the risk-benefi t ratio of these 
patients clearly favours TEA, which is also superior when assessing the outcomes 
after high-risk surgery, such as esofagectomy (223). Opioid-sparing adjuvants, such 
as gabapentinoids, epidural clonidine and adrenaline or systemic ketamine, may 
be administered to patients who have re-thoracotomy, pre-existing chronic pain 
in the surgical area, problems in tolerating opioids or those with a background 
of narcotics abuse. However, convincing evidence is still lacking concerning the 
effi cacy of gabapentinoids for acute post-thoracotomy pain or for their ability to 
prevent persistent pain, even though their antihyperalgesic mechanism of action 
is promising. In addition, intrathecal opioids for thoracotomy patients are not 
administered in our hospital due to their short time span (24 hours) and due to 
the increased risk for respiratory depression that cannot be suffi ciently monitored 
in the surgical ward.
Another safe and effective alternative to TEA after thoracotomy is the 
paravertebral block (PVB) with an infusion of local anaesthetics (166-168, 224). This 
non-invasive method is also feasible in anticoagulated patients when the surgeon 
places the catheter before closing the wound. The action of PVB needs intact pleura 
to form an anterior limit to the paravertebral space and it cannot be used with 
empyema patients whose pleura has been removed by surgical decortication. 
Figure 10 presents one suggestion for the management of acute post-thoracotomy 
pain. 
6.2.5. APS
When invasive pain management methods are used, APS is strongly recommended. 
The APS nurses and anaesthesiologists secure the safety of continuous epidural 
and peripheral nerve blocks, supervise IV-PCA techniques, and are responsible 
for ongoing educational programmes for all those involved in postsurgical pain 
management. These nurses and anaesthesiologists also supervise and audit the 
monitoring of acute pain and the effects of pain relief. In other words, they make 
pain visible. Another benefi t is that APS has also been shown to be cost-effective 
(108-110).
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Preoperative patient assessment (high-risk/low-risk patient?) 
Thoracic epidural analgesia with LA  
+ opioids (e.g.fentanyl) 
(+clonidine/adrenaline) 
 
- high-risk patients (cardiovascular or 
  pulmonary disease) 
- no contraindications 
Alternatives to TEA: 
 
* IV-PCA with strong opioids + ic-block 
* continuous  PVB infusion of LA +/- IV-PCA 
 
- low-risk patients (no severe cardiovascular or 
  pulmonary disease) 
- if TEA contraindicated 
Surgical technique  
- muscle sparing thoracotomy 
- wound closure carefully avoiding 
nerve compression
 
   
Adjuvants for every patient 
- NSAIDs/paracetamol 
 
Adjuvants  for selected patients 
- gabapentinoids 
- systemic ketamine 
Close follow-up by APS in hospital 
Extended follow-up after discharge for problematic patients 
LA=local anaesthetics, ic-block=intercostal nerve block, TEA=thoracic epidural analgesia, 
 
PCA=patient controlled analgesia, PVB=paravertebral block, APS=Acute Pain Service
 
Figure 10. A recommendation for postoperative pain management for thoracotomy.
In Study IV APS was available only fi ve days a week for the patients in the control 
group whereas the patients in the intervention group were seen by the researchers 
every day. Out of the patients in the control group, 76% spent one weekend at hospital 
without the close follow-up of APS. The control patients were discharged after fi ve 
days, which is signifi cantly earlier than the intervention patients (eight days). Thus, 
the intervention patients received more intensive pain management for signifi cantly 
longer, which may partially explain their lower incidence of persistent pain. 
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6.3. PARTICIPANTS IN THE CLINICAL TRIALS VERSUS THE “AS 
USUAL” CONTROLS
In Study IV, persistent post-thoracotomy pain was signifi cantly more prevalent 
among the control patients than the intervention patients (24% versus 3%, 
respectively). It seems that the standard care is not suffi cient in preventing chronic 
pain after thoracic surgery, since the insuffi cient relief of acute pain may predispose 
a patient to persistent postsurgical pain. As regards to Study IV, it was a rather novel 
idea to include the standard care patients who were not involved in the intervention 
study in the control group. Patients who participate in an RCT are carefully selected 
and they may not represent the whole patient population. Moreover, patients in 
an RCT receive extra attention, and that treatment may therefore be better than 
ordinary care. Based on these facts, it is important to compare how the results in 
an RCT correlate with those of the standard care patients. Furthermore, something 
resembling a “Hawthorne effect” occurs when the routine care is improved within 
the trial (225).
It has been suggested that participating in an RCT is likely to produce similar 
outcome results as similar treatment outside the trial. This means that the results 
of RCTs can be applied to usual clinical practice (226, 227). However, the pain 
management and the follow-up of the trial participants may differ signifi cantly from 
those of standard care patients, and that is why comparing the outcomes between 
these groups is informative. This data can be utilized to improve the practice of 
pain management protocols.
In Study IV, the control group consisted of patients not eligible to the intervention 
study, with contraindications to the interventional analgesic methods, signifi cant 
liver, renal or cardiac disease, regular use of analgesics, re-thoracotomy, and 
emergency operation. These patients were treated with standard care of the hospital, 
and the groups differed quite a lot. The control patients may have been more diseased 
than the intervention patients, and emergency operations put some challenges to 
the pain management. Eighty-eight per cent of the controls were operated electively, 
yet. However, psychological vulnerability is thought to be more important risk factor 
for chronic postoperative pain than physical illness (Table 4). 
6.4. CAN WE PREDICT ACUTE AND CHRONIC POSTSURGICAL 
PAIN?
In order to prevent patients from having pain that is severe, acute and persistent, 
it is crucial to identify those patients who are at high risk before they undergo 
surgery. Some predisposing factors for developing chronic post-surgical pain are 
listed in Table 4, and some of these (type of surgery, age, psychological distress 
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and catastrophising) are also signifi cant predictors for acute postoperative pain and 
analgesic consumption (228). In Study I, the cumulative consumption of epidural 
fentanyl was somewhat higher postoperatively in those patients who had chronic pain 
three months after surgery, which is consistent with the literature on this subject. 
Surgery induces peripheral neural activation with central neuroplastic changes. 
In some patients, these phenomena may occur during the transition into a state 
of persistent postoperative pain. The pain threshold reveals the transition point 
where a painless sensation changes to a painful one. The suprathreshold painful 
stimuli – a sensation between the pain threshold and tolerance – may better mimic 
the pain experience that is caused by surgery. In a systematic review (229), pain 
stimuli were applied that were thermal, pressure and electrical, suggesting that 
the high levels of pain intensity that is evoked by a suprathreshold heat stimulus 
were most consistently associated with the stronger postoperative pain of female 
patients. Furthermore, the preoperative quantitative sensory testing (QST) may 
predict persistent postoperative pain, as has been suggested with thoracotomy 
patients. In addition, less effi cient diffuse noxious inhibitory control (DNIC, see 
2.5.1.) and enhanced temporal summation (increasing pain scores after repetitive 
stimuli) have been demonstrated to predict acute and chronic post-thoracotomy 
pain (230-232).  An  electrical stimulus  induced by  Pain Matcher (see 4.3.2.), which 
was also used in Study V, may also have some predictive value as a screening tool 
to identify the patients who are at high risk of acute and persistent postoperative 
pain (233-235). 
Study IV assessed hyperalgesia using two methods: by measuring the hyperalgesic 
area around the scar with a von Frey hair (210), and by a “coughing test”, which was 
introduced as a new measure of hyperalgesia in post-thoracotomy pain (see 4.4.1.). 
Half of the patients in the intervention group had a measurable area of hyperalgesia 
before their discharge and they also had more pain when coughing than those who 
did not have hyperalgesia. However, hyperalgesia did not predict persistent pain. 
Nonetheless, no conclusions can be drawn from this, since the test group was so 
small, and only one patient in that group experienced long-term pain. The duration 
of pain that was assessed after coughing was longer in the NSAID group than in the 
epidural group. The only patient with persistent pain 6 months after the surgery 
had a considerably longer-lasting pain in the coughing test than the other patients 
(60 seconds versus a median of 2 seconds). This type of “coughing test” needs to 
be validated in a larger RCT to determine whether it is clinically valuable. 
By identifying the patients who are at risk of severe, postoperative acute and 
chronic pain, we will be able to offer them more effective pain management that is 
individually tailored. Another benefi t of determining those patients at risk is that 
we can avoid using unnecessary invasive pain treatment methods and analgesics 
with potential adverse effects. At present, preoperative genetic or the QST tests are 
not clinically practical to identify patients at risk. Sipilä et al. (236) have recently 
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studied the identifi cation of preoperative risk factors for developing chronic pain 
after breast cancer surgery. Factors that predicted signifi cant pain six months 
after surgery were preoperative chronic pain, more than four previous operations, 
preoperative pain in the surgical area, high body mass index, smoking and advanced 
age. One feasible method to determine which patients would be in need of invasive 
pain management would be to administer a simple electronic questionnaire by 
email to patients that explores the preoperative risk factors of persistent pain, 
especially anxiety and catastrophising. These patients could be invited to see the 
anaesthesiologist preoperatively. Postoperatively, the screening of hyperalgesia by 
administering “a coughing test” and the recording of the pain intensity and analgesic 
consumption would help the APS trace the patients who would benefi t from a 
longer and a closer follow-up. 
6.5. GABAPENTINOIDS AS PERIOPERATIVE ADJUVANTS
6.5.1. GABAPENTIN AND PREGABALIN
The systematic review of gabapentinoids for perioperative pain control (Study III) 
reveals that the pain relief was signifi cantly better in the gabapentin groups than 
in the control groups. The opioid-sparing effect during the fi rst 24 hours after 
a single preoperative dose of 300-1200 mg of gabapentin ranged from 20-62%, 
and the combined effect was equivalent to a reduction in 30+ 4 mg of morphine. 
These fi ndings are consistent with most other systematic reviews that investigate 
single preoperative doses and the 24-hour effect (115-120). In this current review 
of gabapentinoids, 9 out of 22 studies examined the multiple dosing of gabapentin. 
The main fi nding of Study III is that the analgesic and opioid-sparing effect was 
improved by increasing the preoperative gabapentin dose from 300 mg to 600-1200 
mg, but this improvement was not found for higher doses. After spinal surgery, a 
preoperative dose of 22 mg/kg (about 1200-2000 mg) was required for analgesia 
(122). In a recent Cochrane review (121), gabapentin 250 mg was statistically superior 
to a placebo when administered for already established acute postoperative pain, 
but the NNT of 11 was considered of limited clinical value. This review consisted 
of four unpublished studies with a minor drug dose, and gabapentin was used as 
a stand-alone analgesic for acute pain. 
As a presurgical premedication, the anxiolytic action of gabapentin was 
controversial in Study III. Whereas a dose of 1200 mg was signifi cantly better than 
the placebo (216), it was not as effective as oxazepam (217). Yet recently the valuable 
effect of gabapentin as an anxiolytic premedication has been supported (237). For 
instance, in a review conducted for the present analysis, pregabalin was used in only 
one study, and it was used to treat the established pain after dental surgery (238). 
In addition, concerning the analgesic effi cacy of pregabalin, a high dose of 300 mg 
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was also reported to be superior to 400 mg of ibuprofen (238). Recent literature 
has also provided evidence that pregabalin produces a dose-related reduction in 
postoperative opioid consumption (123), with an effi cient dose of 225-300 mg/day 
postoperatively (125). However, this relatively high dose without stepwise titration 
(as in chronic pain) may be at the expense of adverse effects. The benefi cial effects of 
pregabalin in acute postoperative pain is suggested to be dependent on the type of 
surgery. In other words, the more acute neuropathic pain, the more useful pregabalin 
is (124, 127, 128). Despite these results, in a Cochrane review by Moore et al. (126), 
no clear evidence has been found for the benefi cial effects of pregabalin in acute 
postsurgical pain.
A review by Weinbroum (239) offers the most recent evidence of administering 
gabapentin and pregabalin for acute postoperative pain. When given as adjuvants to 
anaesthesia, gabapentinoids are effective in reducing both pain intensity and opioid 
consumption after surgery. However, their analgesic potential per se in comparison 
with other postoperative analgesics is still not clear, and it is diffi cult to extrapolate 
from one study to another due to the heterogeneity of the operations and the 
varying postoperative requirement of opioids. To reduce anxiety, gabapentin doses 
of 600-1200 mg and pregabalin 150-300 mg preoperatively have been effective. 
Nevertheless, White et al. (240) reported an increased sedation but not a reduced 
state of anxiety before day-case surgery. This was possibly caused by the short 
time between pregabalin and the induction of anaesthesia (60-90 min), and the 
relatively low baseline levels of anxiety in the patients undergoing minor surgery.
The most common transient adverse effects caused by gabapentinoids include 
somnolence and dizziness, headaches, balance problems, peripheral edema, 
sweating, dry mouth, blurred vision, and gastrointestinal symptoms. The severity 
of these problems is generally time- and dose-related (239). According to Study 
III, the numbers-needed-to-harm for gabapentin to produce excessive sedation or 
dizziness were 35 and 12, respectively, and there was some indication of gabapentin 
preventing nausea, vomiting and urinary retention.
Table 10 presents a summary of the characteristics of the gabapentinoids for 
acute pain. It should be noticed that it is not possible to provide the defi nitive 
recommendations for the dosing.
6.5.2. DO GABAPENTINOIDS PREVENT CHRONIC POSTOPERATIVE PAIN?
According to Study III, fi ve trials reported long-term effects when gabapentin 
administration was continued two to ten days postoperatively, with the follow-up 
being from one to six months. Four studies favoured gabapentin to placebo in 
acute pain, and in two of these studies, it was suggested that gabapentin prevents 
chronic pain.
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Parameters Gabapentin Pregabalin
Absorption Ceiling eff ect   Linear
Bioavailability 30-60% >90%
Plasma protein binding <3% 0
Metabolism None None
Drug interactions Unlikely None
Elimination half-life (hours, range) 4.8-8.7 5.5-6.3
Relative potency 1 5-6
Mode of administration oral, t.i.d. oral, b.i.d.
Preoperative doses (mg, range) 300-1600                                    100-300
Daily dose (mg, range) used in acute pain 1800-3600   225-600
Dose adjustment according to renal function Yes Yes
Duration of treatment in the studies 7 days 7 days
Opioid sparing eff ect (% decrease from control group) 20-62 16-60
Main adverse eff ects Dizziness (20%)         
Sedation (20-30%)
 Same as    
gabapentin
t.i.d. = three times daily; b.i.d. = twice daily
In a recent systematic review performed by Clarke et al. (241), the administration 
of the perioperative gabapentinoids showed promising results. Out of eight trials, 
four found that gabapentin decreased the occurrence of chronic pain after more than 
two months. However, to blunt the peripheral and central sensitization processes 
that begin during surgery, it was necessary to give a rather high preoperative dose of 
1200 mg and to continue pharmacological therapy into the postoperative phase. All 
three pregabalin trials demonstrated that pregabalin decreased chronic postsurgical 
pain, and two of those trials also reported an improvement in postoperative patient 
function. In the two trials involving lumbar discectomy (242) and total knee 
arthroplasty (243), a dose of 300 mg was given as premedication before surgery 
and then 25-150 mg twice daily for 2-14 days after surgery. The third pregabalin 
trial studied elderly patients who were undergoing cardiac surgery, and the dose 
for these patients was 150 mg preoperatively, then continuing 75 mg twice daily for 
5 days (244). Due to its more reliable absorption profi le, pregabalin is considered 
to be more promising than gabapentin in this type of surgery. These fi ndings were 
confi rmed by a meta-analysis that concluded that there was an overall moderate-
to-large reduction in chronic postsurgical pain (241).
Table 10. Comparative summary of gabapentin and pregabalin for acute pain. Adapted from Tiippana et 
al. (Study III), Zhang et al. (123), Engelman & Cateloy (125), and Weinbroum (239). 
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6.5.3. WHICH SURGICAL PATIENTS COULD BENEFIT FROM PERIOPERATIVE 
GABAPENTINOIDS?
Currently, gabapentinoids are not offi cially recommended for acute perioperative 
pain. They also have adverse effects that may delay the ambulatory patients’ 
discharge from hospital. Furthermore, a screening tool or diagnostic test that can 
preoperatively identify the patients at risk of developing severe acute or chronic 
postsurgical pain (see Discussion 6.4.) is urgently needed. Gabapentinoids might 
be benefi cial if the patient is scheduled to undergo major surgery that may involve 
a risk of nerve damage (for example, thoracotomy, mastectomy with axillary node 
dissection, limb amputation, spinal surgery, large facial and neck dissections), or he/
she has a pre-existing chronic pain. Additionally, gabapentinoids can be an integral 
part of multimodal analgesia if the patient has diffi culties in tolerating opioids and 
benefi ts from the opioid-sparing effect (for example, elderly people, obese patients 
with sleep apnoea, or opioid addicts). 
Free-fl oating anxiety disorder is an offi cial indication for gabapentinoids, and 
they have been studied as an anxiolytic premedication before surgery with some 
promising results (see chapter 6.5.1.). Anxiety is one of the main risk factors for 
acute and persistent postoperative pain, and gabapentinoids could, therefore, be 
utilized as adjuvant analgesics perioperatively with these psychologically vulnerable 
patients (see chapters 2.5.1 and 6.4., Table 4).
Some evidence suggests that pregabalin attenuates opioid-induced hyperalgesia 
that is caused by remifentanil during surgery. After laparoscopic urologic surgery as 
well as open abdominal hysterectomy surgery, when remifentanil was administered 
during the procedure, pregabalin doses of 150-300 mg have decreased pain intensity, 
the area of hyperalgesia and the mechanical hyperalgesia threshold (245, 246). 
Therefore, patients anaesthetised with the common propofol-remifentanil infusions 
may benefi t from preoperative gabapentinoids, especially after painful operations 
such as a thoracotomy.
Due to a greater bioavailability, pregabalin is superior to gabapentin, and 
the doses of pregabalin should be suffi ciently high: 100-300 mg preoperatively 
as premedication (depending on renal function), continuing with 225-600 mg/
day postoperatively (see Table 10). However, defi nitive recommendations for the 
dosing and the duration of the therapy for gabapentinoids postoperatively cannot 
be provided without further research, and cautious use of these adjuvants is still 
warranted.
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6.6. LAPAROSCOPIC CHOLECYSTECTOMY AS A DAY SURGERY 
OPERATION
Laparoscopic cholecystectomy would appear to be an ideal operation for ambulatory 
surgery because the duration of the surgery is short, the incisions are small, the 
rate of immediate complications is low, and the gastrointestinal homeostasis is 
maintained. Despite this, reports show up to 37% of unplanned overnight admissions 
(1). The results of Study II demonstrated that 95% of the LCC patients scheduled for 
outpatient surgery could be operated on a day-case basis. Smooth ambulatory LCC 
was enabled by using a PONV-preventing anaesthetic technique with multimodal 
pain treatment by making the most of opioid-sparing drugs, such as perioperative 
dexamethasone, NSAIDs or paracetamol and local anesthetics.
Surprisingly, paracetamol was found to be as effective as the coxibs in the 
treatment of pain after LCC. This could be due to the visceral nature of post-LCC 
pain quite resistant to NSAIDs and longer elimination half-life of valdecoxib than 
paracetamol relative to the small dose of 40 mg daily (254, 255). Additionally, the 
role of a placebo effect cannot be ignored, when paracetamol was taken four times 
a day compared with once daily intake of coxib. Dexamethasone decreased the need 
for oxycodone in Phase 2 PACU (2-5 hours after surgery) and should most likely 
be administered earlier, for example, at the induction of anaesthesia. Optimally, 
dexamethasone should be administered one to two hours before surgery (140), 
which may be diffi cult to perform when the patients arrive at the hospital just prior 
to their operation. Furthermore, glucocorticoids have also been found to possess 
more rapid non-genomic effects, which makes the timing of their administration 
less important (141).
Dexamethasone is one of the most potent and longest-acting corticosteroids 
available, with a biologic half-life of 36-72 hours. Murphy et al. (247) reported that 
a single preoperative 8 mg dose of dexamethasone improved the emotional and 
physical state of patients, and also alleviated pain on the day following surgery. 
However, Study II found no difference in pain intensity at home between the 
patients who were treated with or without dexamethasone. This discrepancy may 
be explained by the multimodal analgesic regimen that was utilized in Study II, but 
not in the study by Murphy et al. 
On the fi rst postoperative day and continuing for several days at home (see 
Figure 2/Study II), the referred pain in the right shoulder was suggested to be the 
most common and intense. This disabling pain was more severe and longer-lasting 
than described in other studies, although a rather low-pressure pneumoperitoneum 
(<12 mmHg) was used. To prevent shoulder-tip pain after LCC, it may be that the 
pressure of CO
2
 insuffl ation should be as low as 8 mmHg (248). 
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6. DISCUSSION
6.6.1. THE OPTIMAL ANALGESIC METHOD FOR DAY-CASE LCC PATIENTS
Invasive pain treatment techniques, such as epidural analgesia, are not suitable 
for ambulatory LCC. Based on the current literature (249, 250) and on Study 
II in this thesis, the analgesic regimen could include a single preoperative or 
intraoperative dose of dexamethasone 8-10 mg (251), incisional and intraperitoneal 
local anaesthetics, avoidance of drains, and the regular use of NSAIDs or COX-2 
inhibitors during the fi rst 3-4 postoperative days, possibly starting preoperatively. 
Due to the side effects, prophylactic treatment with postoperative opioids is not 
recommended, but short-acting opioids can be used on demand when needed. Other 
opioid-sparing adjuvants, such as gabapentinoids or NMDA receptor antagonists, 
cannot be recommended for day surgery without large dose-response studies (2, 
252).  
6.7. ADVERSE EFFECTS OF PERIOPERATIVE NSAIDS
In Study IV, the patient levels of S-creatinine or cystatine-C before and after 
thoracotomy were not elevated, and there were no differences in adverse effects 
(for example, differences in urine output, blood loss, or gastrointestinal problems) 
between the pare-/valdecoxib, diclofenac and epidural groups. However, this study 
was underpowered to detect these differences. In Study II, valdecoxib also did not 
cause any serious adverse effects with the day-case LCC patients. Only one patient 
had to discontinue the use of the coxibs at home due to that patient developing a 
fl ushed face. 
Coxibs have been reported to increase the risk of thromboembolic complications 
after coronary artery bypass grafting (CABG) in patients with atherosclerotic disease 
(73), but not after non-cardiac surgery (74, 75). The inhibition of COX-2-dependent, 
vasoprotective prostacyclin without a complete suppression of COX-1-dependent 
platelet function might play a role in their cardiovascular toxicity. However, it is 
now understood that, depending on the extent of inhibition of COX-2, all NSAIDs 
(as well as those that are non-selective) are associated to a varying degree with 
cardiovascular risks (253).
In conclusion, coxibs have very few adverse effects when administered for a 
short period of time to young, healthy patients with no pre-existing thromboembolic 
risk factors. 
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6.8. THE EFFECT OF PARACETAMOL AND TROPISETRON ON 
EXPERIMENTAL PAIN
The demand for opioid-sparing adjuvant drugs after surgery is rapidly growing. 
Because NSAIDs are contraindicated in elderly patients and in patients who are at 
risk for gastrointestinal bleeding, cardiovascular problems, or renal insuffi ciency, 
there is a need for postoperative paracetamol. In addition, 5-HT3 antagonists, 
setrons, are commonly administered to prevent or manage postoperative and 
chemotherapy-induced nausea and vomiting. Laparoscopic cholecystectomy is a 
typical day-case operation with an increased chance of PONV, which jeopardizes 
the discharge of the patients on the day of surgery. For this reason, these patients 
are premedicated with setrons and treated postoperatively with paracetamol, as 
they are in Study II. Assuming that setrons would abolish the analgesic action 
of paracetamol, the daily clinical management of postoperative pain would need 
a complete reassessment. This hypothesis was the basic objective for conducting 
Study V.
In Study V, 2 g of IV paracetamol alone did not induce a measurable analgesic 
effect in the cold pressor, heat pain or electrical pain stimulation tests. It is 
noteworthy that Pickering et al. (29, 30) could demonstrate the analgesic action of 
paracetamol in mechanical and electrical pain stimulation tests, with an oral dose of 
1 g. In Study V, after calculating the sensory and pain scores as a percentage of the 
individual score at baseline (as Pickering et al. did), tropisetron seemed to amplify 
the analgesic action of paracetamol, which is an another fundamental difference 
between these experimental trials (see Fig 3/Study V). The results from Study V 
agree with the evidence from basic research and clinical studies, indicating that 
5-HT3 receptor antagonists may have analgesic properties.
Paracetamol is diffi cult to investigate in experimental pain models, since its 
mechanism of action is still unknown. In two recent reviews, Staahl et al. (113) and 
Olesen et al. (114) concluded that the analgesia from paracetamol is diffi cult to detect 
with traditional pain stimulation tests. The suggestion is that instead of subjective 
pain ratings, the analgesia should probably be assessed by adopting extremely 
sensitive methods, such as evoked brain potentials or EEG. Intravenous (but not 
oral) paracetamol has been shown to reduce central hyperalgesia in continuous 
intracutaneous electrical stimulation tests without any effect on ongoing pain. 
However, this antihyperalgesic effect of paracetamol remains controversial (see 
Table 1/Study V). The pain stimulation tests in Study V caused short-term pain 
that did not induce any central sensitization, which is a possible reason for a lack 
of the analgesic effect of paracetamol.
The reason for paracetamol and tropisetron having a weak analgesic effect as sole 
agents but not when administered together, might reside in the complex interaction 
of the central serotonergic pain pathways (95). The combination of these drugs could 
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6. DISCUSSION
be pronociceptive, enhancing the pain signal at the spinal level, or there could be a 
pharmacokinetic interaction between them. Neither Study V nor the experimental 
trials of Pickering et al. detected an analgesic effect of tropisetron. 
The setrons did not affect the analgesic action of paracetamol in clinical 
studies (93, 94). Before conducting further experimental studies that explore the 
possible interaction between these universally administered drugs, it would fi rst 
be necessary to establish the pain models that reliably demonstrate an analgesic 
effect of paracetamol. Furthermore, the possible intrinsic analgesic action of 5-HT3 
antagonists cannot be ignored. At this point, however, there is no need to avoid the 
concomitant administration of paracetamol and setrons.
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7. LIMITATIONS OF THE PRESENT STUDIES
Due to some limitations, the results of the studies presented in this thesis must be 
interpreted with caution.
Study I was not randomized or controlled, because the anaesthesiologist in 
charge selected the method of pain relief. Furthermore, this study used predominantly 
descriptive statistics. However, the Student’s t-test was utilized when applicable. 
Since the number of patients in the IV-PCA group was small (n=18) and the study 
lacked a randomization and standardization of the pain therapy, it was not possible 
to calculate the statistical comparisons between the treatments.
The activation of the metabolic response to surgery begins immediately after 
the incision, and due to genomic changes, the onset of the action of glucocorticoids 
takes 1-2 hours (140). In Study II, dexamethasone was administered 30 minutes 
before the end of surgery, and the maximum effect seemed to appear after 2-5 
hours just before the patient’s discharge from hospital. Had dexamethasone been 
administered earlier at the induction of anaesthesia, there might also have been 
less pain in PACU 1. However, glucocorticoids may also show more rapid effects 
through membrane receptors (141). 
In Study II there may be several reasons why more patients treated with coxibs 
needed rescue analgesics at home compared with patients treated with paracetamol. 
The visceral pain which involves the autonomic nervous system may be quite 
resistant to NSAIDs alone. The t½ of valdecoxib is 8 h, and the steady-state plasma 
concentrations are reached by day 4 (254), whereas the t½ of paracetamol is 2 h. 
Therefore, the greatest benefi t from valdecoxib may not have been experienced in 
time. Puolakka et al. (255) reported that a 40 mg dose of parecoxib is not effective 
for early postoperative pain after LCC, and doubling the dose improved analgesia. 
Thus it might have been more effective to administer 40 mg of valdecoxib to these 
healthy patients twice per day for 3-4 days at home. Paracetamol was taken four 
times a day compared with the once per day intake of coxib. Therefore, there may 
have also been a placebo effect, which could have been avoided by giving three 
placebo tablets in addition to the one valdecoxib tablet per day.
In Study II, tropisetron was administered to all patients and consequently, the 
speculated interaction between paracetamol and the 5-HT3 antagonists could not 
be analyzed (29, 30).
In Study III, no conclusions can be drawn on the optimal dose and duration 
of the postoperative treatment with gabapentinoids owing to the heterogeneous 
data in the studies.
Study IV is underpowered: the intended sample size was not attained and the 
study had to be prematurely interrupted because valdecoxib was withdrawn globally 
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7. LIMITATIONS OF THE PRESENT STUDIES
in 2005. At the same time, open thoracotomies were becoming increasingly rare 
due to thoracoscopic operations. A prospective, non-standardized control group 
consisting of those patients who did not meet the inclusion criteria for the study and 
who were receiving current standard pain management in the clinic, was used as a 
control group and the data, apart from the questionnaire data, were naturally not 
collected in as they were in the intervention groups. The control patients had more 
cardiovascular and pulmonary diseases than the intervention patients. Statistically, 
this study adopted analytical methods that were primarily descriptive and non-
parametric. However, the minimum number of patients per study arm which is 
accepted in the individual studies for systematic reviews, is 10 patients (209). 
In Study V, the electrical stimulus (Pain Matcher) was identical with that of 
Pickering’s (29), but the cold pressor test displayed slight differences. It was still 
validated, and these small differences cannot explain the differences between the 
results of Study V and Pickering’s fi ndings. These experimental studies included 
only male volunteers, whereas the clinical studies included both genders (93, 94). 
This factor is relevant because the prevalence of the most common forms of pain 
seems to be higher among women than men, and women also report greater pain 
after invasive procedures and after experimentally induced pain. Men may exhibit 
greater DNIC (see 2.5.1.) than women, and this phenomenon may be particularly 
predictive of clinical pain (256). Future studies on the effects and interactions of 
paracetamol would be useful to be conducted separately for men and women.
It is possible that the thermal and electrical stimulation tests in Study V could 
not detect the analgesic effect of paracetamol because the short duration of pain did 
not induce central sensitization. Unfortunately, the interaction between paracetamol 
and tropisetron could not be assessed.
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8. CLINICAL IMPLICATIONS AND FUTURE ASPECTS
Acute and chronic postoperative pain remains a challenge, particularly when 
patients are currently discharged much earlier than they were previously. Most 
clinical studies that report acute pain after surgery focus on the acute phase when 
patients are still in hospital, and there are limited data about the sub-acute phase at 
home. This phase is important because central sensitization continues, predisposing 
the patients to persistent pain. This thesis presents information on the intensity of 
the acute postoperative pain, on the occurrence of chronic post-thoracotomy pain 
as well as the pain experienced during the fi rst week after being discharged from 
hospital. During the fi rst week at home, over 70% of the patients seemed to require 
weak opioids on a daily basis. To prevent persistent post-thoracotomy pain, the 
extended protocol for high quality pain management in hospital covering also the 
sub-acute phase at home, was important. These studies also provide some evidence 
that safe and effective alternatives to thoracic epidural analgesia do exist and that 
these deserve further research.
It seems that standard care is not suffi cient to prevent chronic post-thoracotomy 
pain. The idea to include the standard “as usual” care patients as a control group 
and to compare them with the intervention patients is rather new and it deserves 
further consideration in future studies. 
By identifying the patients at risk of severe postoperative acute and chronic pain, 
this will allow us to individually tailor their pain management, avoiding unnecessary 
invasive methods. At present, all patients are not seen by the anaesthesiologist on 
the day before their surgery. An electronic questionnaire surveying preoperative risk 
factors of acute and persistent pain could be a means to identify the patients who 
would benefi t most from invasive and multimodal pain treatment. Postoperatively, 
patients could be earmarked as to who would benefi t from a longer and closer 
follow-up. This identifi cation could be the screening of hyperalgesia by using simple 
measures, such as “a coughing test” and by recording pain intensity and analgesic 
consumption by the APS. These patients could be seen by anaesthesiologists one to 
three weeks after the surgery in a postsurgery APS follow-up outpatient clinic and 
this would be a new “bridge” between APS and a chronic pain clinic.
The analgesic regimen for ambulatory LCC patients could include a single dose 
of opioid-sparing dexamethasone, incisional and possibly intraperitoneal local 
anaesthetics, as well as regular NSAIDs or COX-2 inhibitors during the fi rst 3-4 
postoperative days. Coxibs were found to be safe when administered to young and 
healthy patients for a short period of time.
The opioid-sparing and pain alleviating role of the gabapentinoids in acute 
pain after surgery was demonstrated in a systematic review. However, acute 
78
8. CLINICAL IMPLICATIONS AND FUTURE ASPECTS
postoperative pain is not yet an offi cial indication for gabapentinoids. This thesis 
offers some suggestions for clinicians regarding the patients who could benefi t from 
perioperative gabapentinoids. However, defi nitive recommendations for the dosing 
and duration of gabapentinoid therapy need to be evaluated in future research.
It was previously suggested that tropisetron abolishes the analgesic effect of 
paracetamol, and some clinicians have avoided concomitant administration of these 
common drugs. However, the analgesic action of paracetamol was impossible to 
detect in experimental tests with subjective pain measure outcomes, and thus no 
conclusions about the interaction can be drawn. To conduct experimental studies 
investigating paracetamol and setrons, pain models that reliably show the analgesic 
effi cacy of paracetamol need to be established. Furthermore, the possible intrinsic 
analgesic action of 5-HT3 antagonists should be taken into account. Currently, 
paracetamol and setrons can be administrated together.
To be able to design clinical studies of persistent post-surgical pain, researchers 
need a better understanding of the mechanisms and risk factors that are involved 
in chronic pain, and the follow-up studies must be suffi ciently long-term. For 
future research in preventing and treating chronic pain, hyperpolarization-
activated cyclic nucleotide-modulated ion channels (HCN type 2) have recently 
been found to serve as a link between infl ammatory and neuropathic pain, and 
selective HCN2-blockers might also be an interesting topic (257, 258). Whereas 
relevant demographic, psychosocial and pain-related risk factors as well as genetic 
factors, and some experimental tests such as temporal summation, DNIC (CPM) 
and electrical stimulation are involved in acute and chronic pain, they are not yet 
clinically practical. 
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9. CONCLUSIONS
1. The incidence of persistent post-thoracotomy pain after 6 months was 3-24% 
in the past decade.
2. Persistent post-thoracotomy pain was more prevalent among the control patients 
who were treated with standard care than the intervention patients involved in 
the study. The acute pain intensity between these groups was similar. However, 
the pain management and follow-up of the trial participants differed substantially 
from those of standard “as usual” care patients. A comparison of the outcomes 
between these groups is informative, and this data can be utilized to improve pain 
management protocols.
3. Although patient controlled epidural analgesia (PCEA) was associated with less 
movement-related pain, both PCEA and IV-PCA morphine provided suffi cient 
analgesia and a low incidence of persistent post-thoracotomy pain, without major 
adverse effects. For epidural versus IV-PCA+NSAIDs, the intensity of dynamic pain 
during physiotherapy was less and the duration of pain after coughing was shorter. 
However, TEA cannot be used in every patient, and a valuable alternative may be 
the IV-PCA + NSAIDs with a strict follow-up.
4. For pain after ambulatory LCC, paracetamol was as effective as pare-/valdecoxib. 
Dexamethasone decreased the need for oxycodone in Phase 2 PACU, and its effect 
was similar to the effect on patients who were treated with paracetamol and coxibs. 
However, compared to those administered paracetamol, more patients treated with 
coxibs needed rescue medication at home. An appropriate anaesthetic technique 
with multimodal pain management enabled smooth outpatient LCC in 95% of the 
study patients.
5. To prevent acute and persistent post-thoracotomy pain, high quality pain 
management in the acute phase that is also extended to the patient’s home for the 
fi rst week after discharge could be more important than any analgesic method per 
se. More attention needs to focus on the regular follow-up of the patients during 
the sub-acute phase at home, especially to those at risk of chronic postoperative 
pain. Moreover, almost half of the LCC patients required some analgesic medication 
one week after discharge. For these patients, shoulder pain was also common and 
intense for several days at home.
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9. CONCLUSIONS
6. Gabapentinoids effectively reduce postoperative pain, opioid consumption (20-
62%) and opioid-related adverse effects postoperatively, with negligible adverse 
effects of their own. Thus far, due to the heterogeneity of the studies, conclusions 
cannot be drawn on the optimal dose, the duration of the treatment, and the long-
term benefi ts of perioperative gabapentinoids. 
7. Paracetamol did not display a measurable analgesic effect in the thermal or 
electrical pain stimulation tests. Therefore, no conclusions can be drawn regarding 
any possible interaction between paracetamol and tropisetron. To design further 
experimental studies on this drug, pain models should be established that reliably 
show an analgesic effect of paracetamol. Furthermore, when studying the interactions 
between paracetamol and 5-HT3 antagonists the possible intrinsic analgesic effect 
of tropisetron should not be ignored. Thus far, there is no fi rm evidence to suggest 
that the use of setrons with paracetamol should be avoided.
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APPENDIX 1
Dear Madam/Sir
You had a lung operation about 6 months ago in Meilahti Hospital. We enquired 
after Your health by telephone one week after discharge from hospital, and by a 
questionnaire three months after that. Now after six months we would still like 
to know how You are, and we would appreciate if You would kindly answer the 
following questions.
We ask Your pain with Visual analogue scale. 
1. If You have any pain around the scar, please mark a cross to this VAS line (X):
a) Your pain at rest 
________________________________________
no pain (0)    worst imaginable pain (10)
b) Your pain when breathing deeply
________________________________________
no pain (0)    worst imaginable pain (10)
c) Your pain when coughing
________________________________________
no pain (0)    worst imaginable pain (10)
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2. Is Your pain around the scar
__  mild
__  moderate
__  severe
 
__  excruciating
__  no pain
3. If You still have pain around the scar, do You feel it
___  all the time
___  not all the time, but daily
___  a few times a week
___  a few times a month
___  only in specifi c situations, please name them_____________________
_______________________________________________________
4. If You do not have pain any more, for how long did it continue after discharge 
from hospital?
___  less than 3 weeks
___  3 weeks – 2 months
___  2 months – 5 months
___  more than 5 months but not any more
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5. Do You have pain, numbness or other symptoms elsewhere than around the 
scar, which might be due to the operation?
___  yes
___  no
If “yes”, please specify: ________________________________________
________________________________________________________
6. If You still have pain around the scar, which of the following activities make it 
worse?
___  I feel pain also at rest
___  getting up from the bed
___  standing
___  walking
___  weather changes
___  feeling depressed
___  carrying things with the arm on the operated side
___  combing hair with the arm on the operated side
___  some other activity: ______________________________________
_______________________________________________________
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7. Does the pain make Your daily activities more diffi cult (e.g. clothing yourself, 
making bed)?
___  not at all
___  a little
___  moderately
___  quite a lot
___  very much
If it does, please specify how: ___________________________________
_______________________________________________________
  
8. Does the pain interfere with Your sleep?
___  yes
___  no
If it does, how often?
___  every night
___  a few times a week
___  less frequently
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9. Have You used pain medication at home for the pain around the scar?
___  yes, daily
___  yes, a few times a week
___  yes, a few times a month
___  no, I have not
If “yes”, please specify which medication: ___________________________
_______________________________________________________
Please name also other medication You use daily (e.g. sleeping pills, antidepressants):
_______________________________________________________
_______________________________________________________
10. Have You received some other treatment than medication for Your pain (e.g. 
local anaesthesia, physiotherapy)?
_______________________________________________________
_______________________________________________________
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11. Have these medications or other treatments been effective for Your pain?
___  not at all
___  a little
___  moderately
___  quite a lot
___  very much
12. Has the intensity of Your pain around the scar changed with time?
___  yes, it has intensifi ed
___  yes, it has diminished
___  it has remained the same
___  no pain any more
13. Have You contacted the hospital because of postoperative problems? Please 
specify:
_______________________________________________________
_______________________________________________________
14. Have You gone through cytostatic or radiotherapy? 
_______________________________________________________
_______________________________________________________
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15. Please draw Your pain areas in the picture enclosed.
If You want to tell something else about Your pain, please write it here or on the 
other side of the paper.
Many thanks for Your trouble!
Elina Tiippana  Eija Nilsson  Eija Kalso
anaesthesiologist anaesthesiologist professor
tel: 4711*  tel: 4711*  tel:4711*
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     Patient number_________
1. postoperative day,
after the telephone interview
Pain during the day, time_________p.m.
pain at rest
______________________________________
0              10
no pain                                  worst imaginable pain
pain at movement (breathing deeply, coughing, activities)
______________________________________
0              10
no pain                                 worst imaginable pain 
Pain in the evening before going to sleep, time_________p.m. 
pain at rest
_______________________________________
0               10
no pain                                   worst imaginable pain 
pain at movement
_______________________________________
0               10
no pain                                   worst imaginable pain 
Where is the pain?___________________________________________
Please describe the nature of the pain? _____________________________
_______________________________________________________
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5)  Pain medication during 24 hours (analgetics, doses, times): ____________
_______________________________________________________
_______________________________________________________
6) Adverse effects from the analgetics?_____________________________
________________________________________________________
________________________________________________________
2. postoperative day
Pain on the morning, time_________a.m.
pain at rest
______________________________________
0             10
no pain                                 worst imaginable pain 
pain at movement (breathing deeply, coughing, activities)
______________________________________
0              10
no pain                                 worst imaginable pain 
Pain during the day or evening, time________p.m.
pain at rest
_______________________________________
0               10
no pain                                  worst imaginable pain 
pain at movement
_______________________________________
0                10
no pain                                   worst imaginable pain 
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3)  Where is the pain?_________________________________________
4)  Please describe the nature of the pain? __________________________
5)  Pain medication during 24 hours (analgetics, doses, times): _____________
_______________________________________________________
_______________________________________________________
6)  Adverse effects from the analgetics? ____________________________
_______________________________________________________
3. postoperative day
1)  Pain on the morning, time_________a.m.
pain at rest
______________________________________
0             10
no pain                                 worst imaginable pain 
pain at movement (breathing deeply, coughing, activities)
______________________________________
0              10
no pain                                 worst imaginable pain 
2)  Pain during the day or evening, time________p.m.
pain at rest
_______________________________________
0               10
no pain                                  worst imaginable pain 
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pain at movement
_______________________________________
0                10
no pain                                   worst imaginable pain 
3) Where is the pain?________________________________________
4) Please describe the nature of the pain?   _________________________
_______________________________________________________
_______________________________________________________
5)  Pain medication during 24 hours (analgetics, doses, times): _____________
_______________________________________________________
_______________________________________________________
6)  Adverse effects from the analgetics? ____________________________
_______________________________________________________
_______________________________________________________
4. postoperative day
1)  Pain on the morning, time_________a.m.
pain at rest
______________________________________
0             10
no pain                                 worst imaginable pain 
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pain at movement (breathing deeply, coughing, activities)
______________________________________
0              10
no pain                                 worst imaginable pain 
2)  Pain during the day or evening, time________p.m.
pain at rest
_______________________________________
0               10
no pain                                  worst imaginable pain 
pain at movement
_______________________________________
0                10
no pain                                   worst imaginable pain 
3) Where is the pain?________________________________________
4) Please describe the nature of the pain?   _________________________
_______________________________________________________
_______________________________________________________
5)  Pain medication during 24 hours (analgetics, doses, times): _____________
_______________________________________________________
_______________________________________________________
6)  Adverse effects from the analgetics? ____________________________
_______________________________________________________
_______________________________________________________
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5. postoperative day
1)  Pain on the morning, time_________a.m.
pain at rest
______________________________________
0             10
no pain                                 worst imaginable pain 
pain at movement (breathing deeply, coughing, activities)
______________________________________
0              10
no pain                                 worst imaginable pain 
2)  Pain during the day or evening, time________p.m.
pain at rest
_______________________________________
0               10
no pain                                  worst imaginable pain 
pain at movement
_______________________________________
0                10
no pain                                   worst imaginable pain 
3) Where is the pain?________________________________________
4) Please describe the nature of the pain?   _________________________
_______________________________________________________
_______________________________________________________
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5)  Pain medication during 24 hours (analgetics, doses, times): _____________
_______________________________________________________
_______________________________________________________
6)  Adverse effects from the analgetics? ____________________________
_______________________________________________________
_______________________________________________________
6. postoperative day
1)  Pain on the morning, time_________a.m.
pain at rest
______________________________________
0             10
no pain                                 worst imaginable pain 
pain at movement (breathing deeply, coughing, activities)
______________________________________
0              10
no pain                                 worst imaginable pain 
2)  Pain during the day or evening, time________p.m.
pain at rest
_______________________________________
0               10
no pain                                  worst imaginable pain 
pain at movement
_______________________________________
0                10
no pain                                   worst imaginable pain 
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3) Where is the pain?________________________________________
4) Please describe the nature of the pain?   _________________________
_______________________________________________________
_______________________________________________________
5)  Pain medication during 24 hours (analgetics, doses, times): _____________
_______________________________________________________
_______________________________________________________
6)  Adverse effects from the analgetics? ____________________________
_______________________________________________________
_______________________________________________________
7. postoperative day ( NB: the questionnaire is a little different from the previous 
ones)
1)  Pain on the morning, time_________a.m.
pain at rest
______________________________________
0             10
no pain                                 worst imaginable pain 
pain at movement (breathing deeply, coughing, activities)
______________________________________
0              10
no pain                                 worst imaginable pain 
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2)  Pain during the day or evening, time________p.m.
pain at rest
_______________________________________
0               10
no pain                                  worst imaginable pain 
pain at movement
_______________________________________
0                10
no pain                                   worst imaginable pain 
3)  Where is the pain?________________________________________
4)  After the operation, when did you feel well enough to manage the daily activities 
normally (dressing, doing the dishes, outdoor activities etc.)? _____________
_______________________________________________________
5)  Do you feel fi t for work one week after the operation?
     __ yes
     __ no;
          If “no”, please specify why? ________________________________
_______________________________________________________
If You like to comment, please write here or on the other side of the paper.
Many thanks for Your trouble!

